Catecholamine carbamate prodrugs for the treatment of Parkinson's disease

By developing carbamate derivative compounds that interact with the peptide transporter PEPT1, the problems of low oral bioavailability and unstable pharmacokinetics of dopamine agonists have been solved, enabling sustained and effective treatment of diseases such as Parkinson's disease.

CN113727712BActive Publication Date: 2024-11-15H LUNDBECK AS
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202080031062.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-05-24
Filing Date
2020-05-19
Publication Date
2024-11-15
Estimated Expiration
2040-05-19

AI Technical Summary

Technical Problem

Existing dopamine agonists for the treatment of Parkinson's disease suffer from low oral bioavailability, unstable pharmacokinetics, and long-term side effects, making it difficult to provide sustained dopamine stimulation and effective D1/D2 agonist therapy.

Method used

We developed carbamate derivatives of (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol as prodrugs, utilizing the interaction between the amino acid or peptide moiety and the peptide transporter PEPT1 to improve oral bioavailability and stabilize pharmacokinetics.

Benefits of technology

This method achieves sustained and highly effective dopamine stimulation from compound (I), providing a longer duration of drug action and higher plasma concentrations, while avoiding the side effects caused by rapid peak concentrations. It is suitable for the treatment of neurodegenerative diseases and disorders such as Parkinson's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003318739710000021
    Figure BDA0003318739710000021
  • Figure BDA0003318739710000051
    Figure BDA0003318739710000051
  • Figure BDA0003318739710000052
    Figure BDA0003318739710000052
Patent Text Reader

Abstract

The present invention provides compounds of formula (Id) as prodrugs of catecholamines for use in treating neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention, and methods of using the compounds of the present invention to treat neurodegenerative or neuropsychiatric diseases and disorders, particularly Parkinson's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention provides compounds that are carbamate derivatives and prodrugs of the dopamine agonist (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, and their use in the treatment of Parkinson's disease and / or other conditions for which treatment with dopamine agonists is therapeutically beneficial, such as but not limited to restless leg syndrome, Huntington's disease and Alzheimer's disease; and also neuropsychiatric diseases and disorders, such as but not limited to schizophrenia, attention deficit hyperactivity disorder and drug addiction. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention. Background Art

[0002] Parkinson's disease (PD) is a common neurodegenerative disorder that becomes more and more common with age, and affects an estimated population of seven to ten million in the world. Parkinson's disease is a multifaceted disease characterized by both motor symptoms and non-motor symptoms. Motor symptoms include resting tremor (tremor), bradykinesia / akinesia (slowness and difficulty of movement), muscle rigidity, postural instability and gait disorders; and non-motor symptoms include neuropsychiatric disorders (such as depression, psychotic symptoms, anxiety, emotional indifference, mild cognitive impairment and dementia) and autonomic dysfunction and sleep disorders (Poewe et al., Nature Review [Natural Review], (2017) Vol. 3 Entry 17013: 1-21).

[0003] A key hallmark of Parkinson's disease pathophysiology is the loss of pigmented dopaminergic neurons in the substantia nigra pars compacta, which provide dopaminergic innervation to the striatum and other brain regions. This progressive neurodegeneration results in a decrease in striatal levels of dopamine, which ultimately leads to a series of changes in the basal ganglia circuitry, culminating in the development of the four cardinal motor features of Parkinson's disease. The primary targets of dopamine in the striatum consist of medium-sized spiny GABAergic neurons (MSNs) that selectively express either D1 or D2 receptors awaiting localized projection. GABAergic MSNs that project to the lateral globus pallidus (also known as the striato-pallido- 'indirect pathway') express D2 receptors (MSN-2); whereas GABAergic MSNs that project to the substantia nigra pars compacta and lateral globus pallidus (also known as the striato-nigra 'direct pathway') express D1 receptors (MSN-1). Depletion of dopamine due to neuronal loss results in unbalanced activity of the two pathways, leading to a significant reduction in thalamic and cortical output activity and, ultimately, movement disorders (Gerfen et al., Science (1990) 250: 1429-32; Delong, (1990) Trends in Neuroscience 13: 281-5; Alexander et Crutcher, (1990) Trends in Neuroscience 13: 266-71; and for review, Poewe et al., Nature Review (2017) Vol. 3 Entry 17013: 1-21).

[0004] The most effective treatment strategies available for patients with Parkinson's disease and aimed at controlling motor symptoms are mainly indirect and direct dopamine agonists. The classic standard and gold standard treatment regimen includes chronic oral intake of L-3,4-dihydroxyphenylalanine (L-DOPA), which is decarboxylated in the brain to form dopamine. Other approaches are to administer dopamine receptor agonists such as apomorphine (apomorphine works on both D1 and D2 receptor subtypes), or pramipexole, ropinirole, etc., which are mainly directed against the D2 receptor subtype. The best motor relief obtained with L-DOPA and apomorphine is due to their activation of both D1 and D2 receptor subtypes, and overall rebalancing of the indirect-direct pathway (i.e., while the D2 agonist only reverses the indirect pathway disorder).

[0005] L-DOPA and apomorphine, which have the structures depicted below, are currently the most effective PD drugs in clinical use.

[0006]

[0007] L-DOPA is a prodrug of dopamine and remains the most effective drug for the treatment of motor Parkinson's disease. However, after several years of treatment (i.e., the honeymoon period), complications arise due to the inherent progression of the disease (persistent loss of dopaminergic neurons) and the poor pharmacokinetic (PK) profile of L-DOPA. Those complications include: 1) dyskinesia, which is abnormal involuntary movement that occurs during the optimal "duration effect" of the drug; and 2) fluctuations, during which the positive effects of L-DOPA disappear and symptoms reappear or worsen (Sprenger and Poewe, CNS Drugs (2013), 27: 259-272).

[0008] Direct dopamine receptor agonists can activate dopamine autoreceptors and postsynaptic dopamine receptors located on medium spiny neurons MSN-1 and MSN-2. Apomorphine belongs to a class of dopamine agonists with 1,2-dihydroxybenzene (catechol) parts. When combined with the phenylethylamine motif, catecholamines usually have low or no oral bioavailability, such as apomorphine. Apomorphine is used clinically in PD treatment, although it is delivered non-orally (typically intermittent subcutaneous administration via a pump or continuous parenteral infusion during the day). For apomorphine, animal studies have shown that transdermal delivery or implants can provide possible forms of administration. However, when studying the delivery of apomorphine from implants in monkeys (Bibbiani et al., Chase Experimental Neurology [experimental neurology] (2005), 192: 73-78), it was found that in most cases, animals must be treated with the immunosuppressant dexamethasone to prevent local irritation and other complications after implantation surgery. Alternative delivery strategies for apomorphine treatment in PD, such as inhaled and sublingual formulations, have been extensively developed (see, e.g., Grosset et al., Acta Neurol Scand. (2013), 128:166-171 and Hauser et al., Movement Disorders (2016), Vol. 32(9):1367-1372). However, these efforts have not yet been used in clinical applications to treat PD.

[0009] An alternative approach to non-oral formulation of catecholamines involves the use of prodrugs that mask the free catechol hydroxyl groups to enable oral administration. However, a known problem associated with the development of prodrugs for clinical use is the difficulty associated with predicting conversion to the parent compound in humans.

[0010] Different ester prodrugs of catecholamines have been reported in the literature, such as enteric-coated N-propyl-noraporphine (NPA) and monopivaloyl esters of apomorphine for duodenal delivery (see, e.g., WO 02 / 100377) and the D1-like agonist adralide (diacetyl prodrug of A-86929) (Giardina and Williams; CNS Drug Reviews (2001), Vol. 7(3):305-316). In humans, adralide undergoes extensive hepatic first-pass metabolism after oral administration and, as a result, has a low oral bioavailability (approximately 4%). In PD patients, intravenous (IV) adralide has antiparkinsonian efficacy comparable to that of L-DOPA (Giardina and Williams; CNS Drug Reviews (2001), Vol. 7(3):305-316).

[0011] In addition to ester prodrugs of catecholamines, an alternative prodrug approach involves masking the two catechol hydroxyl groups as the corresponding methylenedioxy derivatives, or as diacetal derivatives. This prodrug principle has been described, for example, in Campbell et al., Neuropharmacology (1982); 21(10):953-961 and US 4543256, WO 2009 / 026934 and WO 2009 / 026935.

[0012] For catecholamine prodrugs, yet another proposed approach is to form enone derivatives, as suggested in, for example, WO 2001 / 078713 and Liu et al., Bioorganic Med. Chem. (2008), 16: 3438-3444. For further examples of catecholamine prodrugs, see, for example, Sozio et al., Exp. Opin. Drug Disc. (2012); 7(5): 385-406.

[0013] The compound (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol described as the following compound (I) is disclosed in WO2009 / 026934. The trans isomer was previously disclosed in Liu et al., J. Med. Chem. (2006), 49: 1494-1498 and then in Liu et al., Bioorganic Med. Chem. (2008), 16: 3438-3444, which included pharmacological data indicating that the compound had low oral bioavailability in rats. The racemate was first disclosed in Cannon et al., J. Heterocyclic Chem. (1980); 17: 1633-1636.

[0014]

[0015] Compound (I) is a dopamine receptor agonist with mixed D1 and D2 activities. Three prodrug derivatives of Compound (I) are known in the art.

[0016] Liu et al., J. Med. Chem. (2006), 49: 1494-1498 and Liu et al., Bioorganic Med. Chem. (2008), 16: 3438-3444 disclosed enone derivatives having formula (Ia) described below, which were shown to be converted into active compounds (I) in rats.

[0017]

[0018] WO 2009 / 026934 and WO 2009 / 026935 disclose two types of prodrug derivatives of compound (I), including (6aR, 10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxol[4',5':5,6]benzo[1,2-g]quinoline, a methylenedioxy (MDO) derivative having the following formula (Ib):

[0019]

[0020] It has been demonstrated in WO 2010 / 097092 that compound (Ib) is converted to compound (I) in rat and human hepatocytes. In addition, the in vivo pharmacology of compounds (Ia) and (Ib) and the active "parent compound" (I) has been tested in different animal models for Parkinson's disease (WO 2010 / 097092). Compound (I) and both compounds (Ia) and (Ib) were found to be effective, indicating that compounds (Ia) and (Ib) are converted to compound (I) in vivo. All three compounds have been reported to have a longer duration of action than that observed for L-dopa and apomorphine.

[0021] Other prodrugs of compound (I) disclosed in WO 2009 / 026934 and WO 2009 / 026935 are conventional ester prodrugs having the formula (Ic):

[0022]

[0023] Despite the long-standing interest in this area, there is clearly an unmet need for the development of highly effective, well-tolerated and orally active drugs for the treatment of PD. Prodrug derivatives of mixed D1 / D2 agonists that can provide continuous dopaminergic stimulation, giving a stable PK profile, may meet such unmet needs.

[0024] For various compounds containing catechol moieties, carbamate derivatives have been previously proposed and explored as prodrug principles. Several decades ago, carbamate derivatives of apomorphine and N-n-propylnor-apomorphine were proposed as prodrug derivatives (Edward et al. (1976). J. Pharm Sci. [Journal of Pharmaceutical Science] 65 (11): 1682-1685). Apomorphine bis (dimethylcarbamate) has been synthesized and tested in mice, although the pharmacological effects are very limited compared to apomorphine itself, indicating that its conversion to apomorphine is very slow. EP 0352815 demonstrated the oral bioavailability of carbamate derivatives of γ-L-glutamyl-L-dopa for the treatment of Parkinson's disease.

[0025] Prodrugs targeting various amino acid or peptide transporters are known in the art (see, e.g., Vale et al. 2018, Amino acids in the development of prodrugs, Molecules, 23(9), 2318.) In addition, Ninomiya et al. (2011) disclosed amino acid conjugates of tricin and mentioned improved bioavailability after oral administration. In addition, Kim et al. reported that quercetin-amino acid derivatives exhibited favorable cell permeability in vitro through interaction with the peptide transporter PEPT1 (In vitro solubility, stability and permeability of novel quercetin-amino acid (Kim, MK; Park, K.-S.; Yeo, W.-S.; Choo, H.; Chong, Y.), In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. Bioorg. Med. Chem. 2009, 17, 1164-1171.) WO 06014429 discloses prodrugs of cidofovir, which contain amino acid residues or peptides and have affinity for hPEPT1. However, none of these documents discloses catecholamine prodrugs comprising amino acid or peptide moieties. Summary of the invention

[0026] The present invention relates to novel compounds for the treatment of Parkinson's disease. More specifically, the present invention relates to novel carbamate prodrug derivatives of compound (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (compound (I)). Representative compounds (1)-(3) of the present invention have been shown to be particularly useful for oral delivery of compound (I).

[0027] Thus, in a first aspect, there is provided a compound according to formula (Ie)

[0028]

[0029] wherein Y is selected from H and a carbamoyl group having the formula CONR1R2

[0030]

[0031] (CONR1R2), and

[0032] wherein X is selected from H and a carbamoyl group having the formula CONR3NR4

[0033]

[0034] (CONR3R4)

[0035] where Y and X are not both H, and

[0036] wherein R1, R2, R3 and R4 are each independently selected from the group consisting of: H, C 1-6 Alkyl, amino acid, amino acid residue, and peptide;

[0037] or a pharmaceutically acceptable salt thereof.

[0038] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0039] A further aspect of the invention relates to compounds according to formula (Id) for use as medicaments.

[0040] A further aspect of the invention relates to a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, for use in the treatment of a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless leg syndrome or Alzheimer's disease; or for use in the treatment of a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

[0041] Another aspect of the invention relates to a method for treating a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless leg syndrome or Alzheimer's disease; or for treating a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction; the method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (Id) or a pharmaceutically acceptable salt thereof.

[0042] Another aspect of the invention relates to the use of a compound according to formula (Id) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless leg syndrome or Alzheimer's disease; or for treating a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

[0043] definition

[0044] Compounds of the present invention

[0045] References to compounds encompassed by the present invention include free species of the compounds of the present invention (e.g., free base or zwitter ion), pharmaceutically acceptable salts of the compounds of the present invention, such as acid addition salts or base addition salts, and polymorphic and amorphous forms of the compounds of the present invention and their pharmaceutically acceptable salts. In addition, the compounds of the present invention and their pharmaceutically acceptable salts can potentially exist in unsolvated forms as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, etc. The present invention encompasses both solvated and unsolvated forms.

[0046] Pharmaceutically acceptable salts

[0047] In the context of the present invention, pharmaceutically acceptable salts are intended to indicate non-toxic, ie physiologically acceptable salts.

[0048] The term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts, which are salts formed with inorganic and / or organic acids on the nitrogen atom in the parent molecule. The acid can be selected from, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulfuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, malonic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, gentisic acid, saccharin, and sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, naphthalene-2-sulfonic acid, 2-hydroxyethanesulfonic acid and benzenesulfonic acid.

[0049] Further examples of useful acids that form pharmaceutically acceptable salts can be found, for example, in Stahl and Wermuth (eds.) “Handbook of Pharmaceutical salts. Properties, selection, and use”, Wiley-VCH, 2008.

[0050] Prodrug

[0051] In the context of the present invention, the term "prodrug" or "prodrug derivative" indicates a compound that, after administration to a living subject, such as a mammal, preferably a human, is converted in vivo to a pharmacologically active moiety. This conversion preferably occurs in vivo in a mammal, such as in a mouse, rat, dog, minipig, rabbit, monkey and / or human. In the context of the present invention, a "prodrug of compound (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol", or a "prodrug of a compound of formula (I)", or a "prodrug of compound (I)" is understood to be a compound that, after administration, is converted in vivo to compound (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol. The administration may be by conventional routes of administration of pharmaceutical compositions known in the art, preferably by oral administration.

[0052] In the context of the present invention, the terms "parent compound" and "parent molecule" indicate the pharmacologically active portion obtained after conversion of the corresponding prodrug. For example, the "parent compound" of one of compounds (Ia), (Ib), (Ic) or any of the compounds of the present invention is understood to be a compound of formula (I).

[0053] Substituents

[0054] In the context of the present invention, "-" (dash) or "to" may be used interchangeably to indicate a given range, for example the term "C1-C6 alkyl" is equivalent to "C1 to C6 alkyl".

[0055] The term "alkyl" refers to a straight chain (i.e., unbranched) or branched saturated hydrocarbon having from 1 to 6 carbon atoms (including end values). Examples of such groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-butyl and n-hexyl.

[0056] Amino Acids

[0057] The amino acid may be based on any of the twenty common amino acids found in natural synthetic proteins, as long as the residue provides oral bioavailability of the compound (I) of the present invention. Common amino acids include arginine, lysine, aspartic acid, glutamic acid, glutamine, asparagine, histidine, serine, threonine, tyrosine, cysteine, tryptophan, methionine, alanine, isoleucine, leucine, phenylalanine, valine, proline and glycine.

[0058] In some embodiments of the present invention, α-amino acids having both an amino group and a carboxylic acid group attached to the first α-carbon atom are preferred. The amino group attached to the α-carbon is sometimes referred to as the α-amino group. Similarly, the carboxylic acid group attached to the α-carbon is sometimes referred to as the α-carboxyl group. With the exception of the cyclic amino acid proline, α-amino acids have the general formula H2NC α HXCOOH, wherein X is an organic substituent called a "side chain", and the remaining part is called a backbone, wherein the backbone has a (α-) carboxyl group and a (α-) amino group.

[0059] The term "amino acid residue" means an amino acid that lacks a portion of its structure. Thus, for example, when referring to an amino acid residue of glycine in this article, it is understood that the amino acid residue is a glycine that lacks a portion of its structure. Examples include α-amino acids that lack the OH portion of the α-carboxyl group or lack the H portion of the α-amino group. Also included in the definition of amino acid residue are amino acids that lack a portion of their side chain, such as serine that lacks the H portion of the side chain -OH group.

[0060] The amino acid residues can also be based on modified or uncommon amino acids. Examples of modified or uncommon amino acids include, but are not limited to, 2-aminoadipic acid, 3-aminoadipic acid, β-alanine, 2-aminobutyric acid, pipecolic acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-diaminobutyric acid, desmosine, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, hydroxylysine, allohydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, isodesmosine, N-methylglycine, N-methylisoleucine, N-methylvaline, norvaline, norleucine, ornithine, and homoserine.

[0061] Similarly, a peptide, such as a dipeptide or tripeptide, may comprise any of the twenty common amino acids and any modified or uncommon amino acids, as long as the peptide supports the oral bioavailability of the Compound (I)-carbamate derivative.

[0062] Both the (D) and (L) stereoisomers of amino acid residues can be incorporated into the compounds of the present invention. When the configuration is not specified, the amino acid or residue may have configuration (D), (L) or (DL). For the purposes of this application, unless expressly indicated to the contrary, the named amino acid should be interpreted as including the (D) or (L) stereoisomer. In a specific embodiment of the present invention, the amino acid residue is an L-amino acid, and the peptide is prepared from L-amino acids.

[0063] A derivative of an amino acid residue is an amino acid residue in which a portion of its structure is replaced by an atom or a molecular group. Examples of such derivatives include, but are not limited to, ester derivatives having an -OR group replacing an α-carboxyl-OH group, wherein R is an alkyl or alkenyl group. In a specific embodiment, R is a C1-C20 alkyl or alkenyl group. A dipeptide or tripeptide derivative is a peptide containing at least one amino acid residue derivative.

[0064] Pharmacokinetic Definitions and Abbreviations

[0065] As used herein, "PK profile" is an abbreviation for "pharmacokinetic profile". The pharmacokinetic profiles and pharmacokinetic parameters described herein are based on plasma concentration-time data for a compound of formula (I) obtained using a non-compartmental model following oral administration of the compound of the invention. The abbreviated PK parameters are: C max (maximum concentration); t max (reach C max time); t 1 / 2 (half-life); AUC 024 (area under the curve from the time of dosing and up to 24 hours post-dose) and "exposure at 24 hours" is the plasma concentration of the compound of formula (I) as measured 24 hours post-dose.

[0066] Therapeutically effective amount

[0067] In the context of the present invention, the term "therapeutically effective amount" of a compound of the present invention means an amount sufficient to alleviate, retard, partially retard, remove or delay the clinical manifestations of a given disease and its complications in a therapeutic intervention comprising the administration of the compound. An amount sufficient to achieve this purpose is defined as a "therapeutically effective amount". The effective amount for each purpose will depend, for example, on the severity of the disease or injury and the weight and general state of the subject. It should be understood that determining an appropriate dose can be achieved using routine experimentation by constructing a matrix of values ​​and testing different points in the matrix, all within the ordinary skill of a trained physician.

[0068] In the context of the present invention, a "therapeutically effective amount" of a compound of the present invention indicates an amount of the compound of the present invention which, when administered (preferably by oral route) to a mammal (preferably a human), is able to provide an amount of compound (I) sufficient to alleviate, arrest, partially arrest, eliminate or delay the clinical manifestations of a given disease and its complications.

[0069] Treatment and treating

[0070] In the context of the present invention, "treatment" or "treating" is intended to indicate the management and care of a patient with the purpose of alleviating, arresting, partially arresting, eliminating the clinical manifestations of a disease or delaying its progression. The patient to be treated is preferably a mammal, in particular a human being.

[0071] Conditions treated

[0072] The compounds of the invention are intended for use in the treatment of neurodegenerative diseases and disorders, such as Parkinson's disease and / or other conditions for which treatment with a dopamine agonist is therapeutically beneficial.

[0073] Therapeutic indications include various central nervous system disorders characterized by motor and / or non-motor disorders and for which part of the underlying pathophysiology is a disorder of striatal-mediated circuits. Such dysfunctions can be seen in neurodegenerative diseases such as, but not limited to, Parkinson's disease (PD), restless leg syndrome, Huntington's disease, and Alzheimer's disease, as well as neuropsychiatric disorders such as, but not limited to, schizophrenia, attention deficit hyperactivity disorder, and drug addiction.

[0074] In addition to neurodegenerative diseases and disorders, other conditions where an increase in dopaminergic turnover may be beneficial improve different aspects of mental function, including cognition. It may also have a positive effect in depressed patients, and it may also be used as an appetite suppressant to treat obesity, and for the treatment of drug addiction. It may improve negative, positive, and cognitive symptoms of mild brain dysfunction (MBD), sleeping sickness, attention deficit hyperactivity disorder, and potentially, schizophrenia.

[0075] Restless leg syndrome (RLS) and periodic limb movement disorder (PLMD) are alternative indications that are clinically treated with dopamine agonists. In addition, impotence, erectile dysfunction, SSRI-induced sexual dysfunction, ovarian hyperstimulation syndrome (OHSS) and certain pituitary tumors (prolactinomas) may also be improved by treatment with dopamine agonists. Dopamine is involved in the regulation of the cardiovascular and renal systems, and therefore renal failure and hypertension can be considered as alternative indications for the compounds of the present invention.

[0076] The present invention encompasses the use of the compounds of the present invention for the treatment of the diseases and disorders listed above.

[0077] combination

[0078] In one embodiment of the present invention, the compound of formula (Ie) is used as a stand-alone treatment as the sole active compound. In another embodiment of the present invention, the compound of formula (Ie) can be used in combination with other agents that can be used to treat neurodegenerative diseases or disorders, such as Parkinson's disease. As used herein in the context of the method of the present invention (including the combined administration of a therapeutically effective amount of a compound of formula (Ie) and another compound, which can be used to treat a neurodegenerative disease or disorder), the terms "combined use", "combined with..." and "combination of..." etc. are intended to mean the administration of a compound of formula (Ie) simultaneously or sequentially (in any order) with the other compounds.

[0079] The two compounds can be administered simultaneously or there is a time interval between the administration of the two compounds. The two compounds can be administered as part of the same pharmaceutical preparation or composition or in a separate pharmaceutical preparation or composition. The two compounds can be administered on the same day or on different days. They can be administered by the same route, such as by oral administration, subcutaneous injection, by transdermal administration, by depot type, by intramuscular injection or intravenous injection; or by different routes, wherein one compound is, for example, administered orally or placed by a depot, and another compound is, for example, injected. The two compounds can be administered by the same dosing regimen or intervals, such as once or twice a day, weekly, or monthly; or by different dosing regimens, such as wherein one compound is administered once a day, and another compound is administered twice a day or weekly or monthly.

[0080] In some cases, when treatment with a compound of formula (Ie) is initiated, the patient to be treated may already be treated with one or more other compounds useful for treating a neurodegenerative disease or disorder. In other cases, when treatment with one or more other compounds useful for treating a neurodegenerative disease or disorder is initiated, the patient may already be treated with a compound of formula (Ie) or (Id). In other cases, treatment with a compound of formula (Ie) and treatment with one or more other compounds useful for treating a neurodegenerative disease or disorder are initiated simultaneously.

[0081] Compounds for combination therapy

[0082] In the context of the present invention, the compound to be used in combination with the compound of formula (Ie) can be selected, for example, from L-DOPA, droxidopa, foliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, and antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole.

[0083] In addition to small molecules, compounds for combination may also include emerging biologic approaches in the treatment of neurodegenerative diseases or disorders, such as antibodies targeting α-synuclein, tau or A-β proteins.

[0084] Route of administration

[0085] Pharmaceutical compositions comprising a compound of formula (Ie) (as the sole active compound or in combination with another active compound) can be specifically formulated for administration by any suitable route, such as oral, rectal, nasal, buccal, sublingual, pulmonary, transdermal and parenteral (e.g., subcutaneous, intramuscular and intravenous) routes. In the context of the present invention, the oral route is the preferred route of administration.

[0086] It will be appreciated that the route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient.

[0087] Pharmaceutical preparations and excipients

[0088] Hereinafter, the term "excipient" or "pharmaceutically acceptable excipient" refers to pharmaceutical excipients, including but not limited to carriers, fillers, diluents, antiadherents, binders, coatings, colorants, disintegrants, flavoring agents, glidants, lubricants, preservatives, sorbents, sweeteners, solvents, vehicles and adjuvants.

[0089] The present invention also provides a pharmaceutical composition comprising a compound of formula (Ie) (such as one of the compounds disclosed in the experimental section herein). The present invention also provides a method for making a pharmaceutical composition comprising a compound of formula (Ie). The pharmaceutical composition according to the present invention can be formulated with pharmaceutically acceptable excipients according to conventional techniques, such as those disclosed in: Remington, The Science and Practice of Pharmacy, 22nd edition (2012), editor Allen, Loyd V., Jr.

[0090] Preferably, the pharmaceutical composition comprising the compound of the present invention is a pharmaceutical composition for oral administration. Pharmaceutical compositions for oral administration include solid oral dosage forms, such as tablets, capsules, powders and granules; and liquid oral dosage forms, such as solutions, emulsions, suspensions and syrups, as well as powders and granules to be dissolved or suspended in appropriate liquids.

[0091] Solid oral dosage forms can be presented as discrete units (e.g., tablets or hard or soft capsules), each containing a predetermined amount of active ingredient and preferably one or more suitable excipients. Where appropriate, solid dosage forms can be prepared with coatings, such as enteric coatings, or they can be formulated to provide modified release of the active ingredient, such as delayed release or extended release, according to methods well known in the art. Where appropriate, solid dosage forms can be dosage forms that disintegrate in saliva, such as orodispersible tablets.

[0092] Examples of excipients suitable for solid oral preparations include, but are not limited to, microcrystalline cellulose, corn starch, lactose, mannitol, povidone, cross-linked sodium carboxymethylcellulose, sucrose, cyclodextrin, talc, gelatin, pectin, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose. Similarly, solid preparations may include excipients known in the art for delayed or extended release preparations, such as glyceryl monostearate or hypromellose. If a solid material is used for oral administration, the preparation may be prepared, for example, by mixing the active ingredient with a solid excipient and then compressing the mixture in a conventional tablet press; or the preparation may be placed in a hard capsule, for example, in the form of a powder, pill, or mini tablet. The amount of solid excipient will vary widely, but will typically be in the range of from about 25 mg to about 1 g / dosage unit.

[0093] Liquid oral dosage forms can be presented as, for example, elixirs, syrups, oral drops or liquid-filled capsules. Liquid oral dosage forms can also be presented as powders for solutions or suspensions in aqueous or non-aqueous liquids. Examples of excipients suitable for liquid oral formulations include, but are not limited to, ethanol, propylene glycol, glycerol, polyethylene glycol, poloxamer, sorbitol, polysorbate, monoglycerides and diglycerides, cyclodextrins, coconut oil, palm oil and water. Liquid oral dosage forms can be prepared, for example, by dissolving or suspending the active ingredient in an aqueous or non-aqueous liquid or by incorporating the active ingredient into an oil-in-water or water-in-oil liquid emulsion.

[0094] Additional excipients (eg, coloring agents, flavoring agents, preservatives, etc.) may be used in both solid and liquid oral preparations.

[0095] Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous solutions, dispersions, suspensions or emulsions for injection or infusion, concentrates for injection or infusion, and sterile powders to be reconstituted in sterile solutions or dispersions for injection or infusion prior to use. Examples of excipients suitable for parenteral formulations include, but are not limited to, water, coconut oil, palm oil, and cyclodextrin solutions. Aqueous formulations should be appropriately buffered if necessary and made isotonic with sufficient saline or glucose.

[0096] Other types of pharmaceutical compositions include suppositories, inhalants, creams, gels, skin patches, implants, and formulations for buccal or sublingual administration.

[0097] It is essential that the excipients used in any pharmaceutical formulation are suitable for the intended route of administration and are compatible with the active ingredient.

[0098] dose

[0099] In one embodiment, the compound of the invention is administered in an amount from about 0.0001 mg / kg body weight to about 5 mg / kg body weight per day. In particular, the daily dose may be in the range of 0.001 mg / kg body weight to about 2 mg / kg body weight per day. The exact dose will depend on the frequency and mode of administration, the sex, age, weight and general condition of the subject to be treated, the nature and severity of the condition to be treated, any concomitant disease to be treated, the desired therapeutic effect, and other factors known to those skilled in the art.

[0100] Typical oral dosages for adults will be in the following range: 0.01-100 mg / day of the compound of the invention, such as 0.05-50 mg / day, such as 0.1-10 mg / day or 0.1-5 mg / day. Conveniently, the compound of the invention is administered in a unit dosage form containing the compound in an amount of about 0.01 to 50 mg, such as 0.05 mg, 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg or up to 50 mg of the compound of the invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0101] Figure 1: Schematic representation of the conversion of compounds (1)-(3) of the present invention into compound (I). Solid arrows: transformations demonstrated in vitro and in vivo. Striped arrows: transformations demonstrated in vivo. DETAILED DESCRIPTION

[0102] The inventors of the present invention have identified novel compounds which are carbamate derivatives and prodrugs of (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol [Compound (I)] that are dual D1 / D2 agonists (see, e.g., WO 2009 / 026934).

[0103] The compound of the present invention is a carbamate derivative of compound (I).

[0104] The present inventors have found that oral administration of representative compounds (1)-(3) of the present invention provides systemic exposure of compound (I) in plasma in Wistar rats, indicating the usefulness of the compounds as orally active prodrugs of compound (I).

[0105] For compounds tested in vivo, the dose was corrected by molecular weight to a dose equal to 300 μg / kg of compound (Ib) (corresponding to 287 μg / kg of compound (I)). It was found that oral administration of compounds (Ia) and (Ib) to Wistar rats resulted in early and high peak concentrations of compound (I). In humans, such high peak concentrations may be associated with dopaminergic side effects, such as nausea, vomiting and mild headaches. In contrast, for the compounds of the present invention, a slower absorption rate was observed, with sustained exposure to compound (I), avoiding rapid peak plasma concentrations. Therefore, in Wistar rats, the plasma exposure of compound (I) was maintained for 24 hours, although the AUC obtained by compound (I) was lower than that obtained after administration of compounds (Ia) and (Ib). However, because the peak concentration of compound (I) that is expected to drive side effects is lower, a higher dose of the compound of the present invention can be administered, thereby potentially achieving a higher overall plasma concentration of compound (I) compared to the results achievable from administration of compounds (Ia) and (Ib). When studying the PK properties of compound (Ic), the inventors of the present invention found that the plasma concentration of compound (I) was extremely low, making compound (Ic) unsuitable for oral administration as a prodrug of compound (I), and confirmed that the oral bioavailability of the compound of the present invention is highly unpredictable. The PK parameters used for PK studies in Wistar rats are listed in Table 4.

[0106] As described in Example 1, the bioconversion of compounds (1)-(3) of the present invention to compounds of formula (I) was also evaluated by incubation in human plasma. For the parent compound (I) itself, a short half-life was observed in the plasma assay, which may explain that for one of the compounds of the present invention, the formation of compound (I) could not be determined, as it may be metabolized at the same time as it is formed. For all compounds (1)-(3) of the present invention, conversion to compound (I) was demonstrated in vitro or both in vivo and in vitro, see Table 1 and Figure 1 below.

[0107] Table 1: In vitro and in vivo transformation of compounds (1) to (3) of the present invention

[0108]

[0109] In summary, the compounds of the present invention (as represented by compounds (1)-(3)) can be used as orally active prodrugs of compound (I) and have been observed in rats to provide a PK profile that avoids the peak C observed for known prodrugs (Ia) and (Ib). max , and provided a significantly higher AUC for Compound (I) compared to Compound (Ic).

[0110] Finally, an important issue associated with compound (Ib) is that it is an agonist of the 5-HT2B receptor. Since 5-HT2B receptor agonists have been implicated in the pathogenesis of valvular heart disease (VHD) after long-term exposure, such compounds are not suitable for the treatment of chronic diseases (Rothman et al., Circulation (2000), 102: 2836-2841; and Cavero and Guillon, J. Pharmacol. Toxicol. Methods (2014), 69: 150-161). Therefore, an additional advantage of compounds (1)-(3) of the present invention is that these compounds are not 5-HT2B agonists, see Example 2 and Table 3.

[0111] Peptide transporters (PEPT1 and PEPT2) and LAT1 and LAT2 have been used as targets for prodrugs, where an amino acid or peptide has been attached to an active compound by using an ester or carbamate bond. L-amino acid transporters 1 (LAT1) and 2 (LAT2) are responsible for the transport of large neutral amino acids from the extracellular fluid into the cell. The natural substrates of LAT1 are large neutral amino acids such as L-leucine, L-tryptophan, and L-phenylalanine. In addition, PEPT1 is known to play a key role in the absorption of a variety of drugs and prodrugs from the intestine. PEPT1 is located in the apical enterocyte membrane of the upper small intestine, where PEPT1 acts as a symporter using the electrochemical proton gradient as its driving force. Human PEPT1 (hPEPT1) contains 708 amino acids oriented in 12 transmembrane domains. Since PEPT1 is an important amino acid / dipeptide / tripeptide transporter in human enterocytes, the transport of hundreds of different possible dipeptides, thousands of possible tripeptides, and a variety of drugs and prodrugs means that this transporter has a broad substrate specificity.

[0112] In one embodiment of the present invention, the carbamate derivative of compound (I) is capable of being transported by one or more peptide transporters, such as PEPT1, PEPT2, LAT1 and LAT2. In a more specific embodiment of the present invention, the carbamate derivative of compound (I) as defined herein is capable of being transported by PEPT1.

[0113] It has been shown that PEPT1 has a high affinity for L-amino acids or peptides comprising L-amino acids. Therefore, in one embodiment of the invention, the amino acid or amino acid residue is an L-amino acid or L-amino acid residue. Similarly, in one embodiment of the invention, the peptide comprises or consists of L-amino acids.

[0114] The amino acid or amino acid residue according to the present invention can be any of the twenty common amino acids found in natural synthetic proteins. Therefore, in one embodiment, the amino acid or amino acid residue is selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, glutamine, asparagine, histidine, serine, threonine, tyrosine, cysteine, tryptophan, methionine, alanine, isoleucine, leucine, phenylalanine, valine, proline and glycine.

[0115] In one embodiment of the invention, the peptide comprises amino acid residues of two or more amino acids selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, glutamine, asparagine, histidine, serine, threonine, tyrosine, cysteine, tryptophan, methionine, alanine, isoleucine, leucine, phenylalanine, valine, proline and glycine.

[0116] In some studies, PEPT1 has been found to have a preference for specific amino acids or peptides containing specific amino acids such as phenylalanine, valine, leucine, isoleucine, glycine and alanine. Therefore, in one embodiment of the present invention, the amino acid is selected from the group consisting of: phenylalanine, valine, leucine, isoleucine, glycine and alanine, wherein the L-form of the amino acids in this group is preferred. In an even more specific embodiment of the present invention, the amino acid is selected from the group consisting of: phenylalanine and glycine.

[0117] Similarly, in one embodiment, the peptide comprises or consists of one or more amino acids selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine, wherein the L-form of the amino acids in this group is preferred. In an even more specific embodiment of the invention, the peptide comprises one or more amino acids selected from the group consisting of phenylalanine and glycine.

[0118] PEPT1 can transport single amino acid derivatives as well as dipeptide derivatives and tripeptide derivatives of the active compound. Therefore, in one embodiment of the present invention, the carbamate derivative of compound (I) comprises an amino acid residue.

[0119] In another embodiment of the present invention, the compounds of the present invention comprise a dipeptide or a tripeptide.

[0120] In one embodiment of the invention, the compounds of the invention comprise a dipeptide comprising or consisting of one or more amino acids selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine, wherein the L-form of the amino acids in the group is preferred. In a specific embodiment of the invention, the compounds of the invention comprise a dipeptide comprising or consisting of one or more amino acids or amino acid residues selected from the group consisting of phenylalanine and glycine. In an even more specific embodiment, the compounds of the invention include a dipeptide comprising a phenylalanine residue. In an even more specific embodiment, the compounds of the invention include a dipeptide comprising a glycine residue. In a specific embodiment of the invention, the dipeptide consists of phenylalanine and glycine residues.

[0121] In another specific embodiment, the compound of the present invention comprises a dipeptide comprising or consisting of at least two of the amino acid residues selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine.

[0122] In a specific embodiment of the present invention, the dipeptide consists of two alanine residues, or two phenylalanine residues, or two leucine residues, or two isoleucine residues, or two valine residues.

[0123] In one embodiment of the present invention, the compound of the present invention comprises a tripeptide comprising or consisting of one or more amino acids selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine, wherein the L-form of the amino acids in this group is preferred. In a specific embodiment of the present invention, the compound of the present invention comprises a tripeptide comprising or consisting of one or more amino acids or amino acid residues selected from the group consisting of phenylalanine and glycine.

[0124] In another specific embodiment, the compound of the invention comprises a tripeptide comprising or consisting of at least two of the amino acid residues selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine.

[0125] In another specific embodiment, the compound of the invention comprises a tripeptide comprising or consisting of at least three of the amino acid residues selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine.

[0126] In a specific embodiment of the present invention, the tripeptide consists of three alanine residues, or three phenylalanine residues, or three leucine residues, or three isoleucine residues, or three valine residues.

[0127] Thus, in a more specific embodiment, the tripeptide comprises or consists of the amino acid residues of phenylalanine, glycine and alanine.

[0128] In another more specific embodiment, the tripeptide comprises or consists of amino acid residues of phenylalanine, glycine, and isoleucine.

[0129] In another more specific embodiment, the tripeptide comprises or consists of amino acid residues of phenylalanine, glycine, and leucine.

[0130] In another more specific embodiment, the tripeptide comprises or consists of the amino acid residues of phenylalanine, glycine, and valine.

[0131] In another more specific embodiment, the tripeptide comprises or consists of amino acid residues of phenylalanine, alanine, and isoleucine.

[0132] In another more specific embodiment, the tripeptide comprises or consists of amino acid residues of phenylalanine, alanine, and leucine.

[0133] In another more specific embodiment, the tripeptide comprises or consists of the amino acid residues of phenylalanine, alanine and valine.

[0134] In another more specific embodiment, the tripeptide comprises or consists of amino acid residues of phenylalanine, isoleucine and leucine.

[0135] In another more specific embodiment, the tripeptide comprises or consists of the amino acid residues of phenylalanine, isoleucine and valine.

[0136] In another more specific embodiment, the tripeptide comprises or consists of the amino acid residues of phenylalanine, leucine, and valine.

[0137] In another more specific embodiment, the tripeptide comprises or consists of the amino acid residues of phenylalanine, leucine, and valine.

[0138] In another more specific embodiment, the tripeptide comprises or consists of amino acid residues of glycine, alanine, and isoleucine.

[0139] In another more specific embodiment, the tripeptide comprises or consists of amino acid residues of glycine, alanine, and leucine.

[0140] In another more specific embodiment, the tripeptide comprises or consists of the amino acid residues of glycine, alanine and valine.

[0141] In another more specific embodiment, the tripeptide comprises or consists of amino acid residues of glycine, isoleucine and leucine.

[0142] In another more specific embodiment, the tripeptide comprises or consists of the amino acid residues of glycine, isoleucine, and valine.

[0143] In another more specific embodiment, the tripeptide comprises or consists of the amino acid residues of glycine, leucine, and valine.

[0144] In another more specific embodiment, the tripeptide comprises or consists of the amino acid residues of isoleucine, leucine, and valine.

[0145] As mentioned above, peptide transporters such as hPEPT1 are capable of transporting dipeptides. In a particular embodiment, the compound of the invention comprises a dipeptide comprising or consisting of at least two of the amino acid residues selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine.

[0146] In another specific embodiment, the compound of the present invention comprises a dipeptide consisting of two of the amino acid residues selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine.

[0147] In a specific embodiment of the present invention, the dipeptide consists of two alanine residues, or two phenylalanine residues, or two leucine residues, or two isoleucine residues, or two valine residues.

[0148] In specific embodiments, the compounds of the invention include a dipeptide comprising a phenylalanine residue.

[0149] In another specific embodiment, the compounds of the present invention include a dipeptide comprising a glycine residue.

[0150] Therefore, in a more particular embodiment of the present invention, the peptide comprises or consists of amino acid residues of phenylalanine and alanine.

[0151] In another more specific embodiment of the present invention, the peptide consists of amino acid residues of phenylalanine and glycine.

[0152] In another more specific embodiment of the present invention, the peptide comprises or consists of amino acid residues of phenylalanine and isoleucine.

[0153] In another more specific embodiment of the present invention, the peptide comprises or consists of amino acid residues of phenylalanine and leucine.

[0154] In another more specific embodiment of the present invention, the peptide comprises or consists of the amino acid residues of phenylalanine and valine.

[0155] In another more specific embodiment of the present invention, the peptide comprises or consists of amino acid residues of alanine and glycine.

[0156] In another more specific embodiment of the present invention, the peptide comprises or consists of amino acid residues of alanine and isoleucine.

[0157] In another more specific embodiment of the present invention, the peptide comprises or consists of amino acid residues of alanine and leucine.

[0158] In another more specific embodiment of the present invention, the peptide comprises or consists of the amino acid residues of alanine and valine.

[0159] In another more specific embodiment of the present invention, the peptide comprises or consists of amino acid residues of glycine and isoleucine.

[0160] In another more specific embodiment of the present invention, the peptide comprises or consists of amino acid residues of glycine and leucine.

[0161] In another more specific embodiment of the present invention, the peptide comprises or consists of the amino acid residues of glycine and valine.

[0162] In another more specific embodiment of the present invention, the peptide comprises or consists of isoleucine and leucine amino acid residues.

[0163] In another more specific embodiment of the present invention, the peptide comprises or consists of the amino acid residues of isoleucine and valine.

[0164] In another more specific embodiment of the present invention, the peptide comprises or consists of the amino acid residues of leucine and valine.

[0165] In a specific embodiment of the present invention, one or more of R1, R2, R3 and R4 is an amino acid, an amino acid derivative or a peptide connected through the Cα atom of the amino acid, amino acid residue or peptide.

[0166] In a specific embodiment of the invention, one or more of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide linked via the Cα atom of a glycine residue.

[0167] In a preferred embodiment of the present invention, one or more of R1, R2, R3 and R4 is an amino acid, an amino acid derivative or a peptide connected via the carboxyl group of the amino acid, amino acid residue or peptide.

[0168] In a preferred embodiment of the present invention, one or more of R1, R2, R3 and R4 are amino acids or amino acid derivatives connected via the backbone carboxyl group of the amino acid or amino acid residue.

[0169] In another embodiment of the present invention, one or more of R1, R2, R3 and R4 is phenylalanine or a derivative thereof attached via a benzyl group of an amino acid or amino acid residue side chain.

[0170] In another embodiment of the present invention, one or more of R1, R2, R3 and R4 is phenylalanine or a residue thereof attached via a benzyl group of the amino acid or amino acid residue side chain.

[0171] In a preferred embodiment of the present invention, one or more of R1, R2, R3 and R4 is a peptide linked via the carboxyl group at the C-terminus of the peptide backbone.

[0172] In a preferred embodiment of the present invention, one or more of R1, R2, R3 and R4 is a dipeptide linked via the carboxyl group at the C-terminus of the peptide backbone.

[0173] In a preferred embodiment of the present invention, one or more of R1, R2, R3 and R4 is a tripeptide linked via the carboxyl group at the C-terminus of the peptide backbone.

[0174] The compounds of the invention are useful for treating neurodegenerative diseases and disorders, such as Parkinson's disease and / or other conditions for which treatment with a dopamine agonist is therapeutically beneficial. Compounds suitable for oral administration have the potential to provide a new treatment paradigm for Parkinson's disease.

[0175] In one embodiment of the invention, the compounds are used as a stand-alone treatment for a neurodegenerative disease or disorder. In another embodiment of the invention, the compounds are used in combination with other agents for the treatment of PD, such as compounds selected from the group consisting of L-DOPA, droxidopa, foliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole; or in combination with antibodies targeting alpha-synuclein, tau protein or A-beta protein.

[0176] Embodiments of the present invention

[0177] In the following, some specific embodiments of the present invention are disclosed. The first embodiment is denoted as E1, the second embodiment is denoted as E2, etc.

[0178] E1. A compound according to formula (Id)

[0179]

[0180] in

[0181] R1, R2, R3 and R4 are each independently selected from H and C 1-6 alkyl;

[0182] or a pharmaceutically acceptable salt thereof.

[0183] E2. A compound or pharmaceutically acceptable salt according to Embodiment E1 wherein R1=R3 and R2=R4.

[0184] E3. A compound or pharmaceutically acceptable salt according to any one of embodiments E1-E2, wherein

[0185] R1 and R3 are both H and R2 and R4 are the same C 1-6 Alkyl; or

[0186] R1 and R3 are the same C 1-6 Alkyl and R2 and R4 are both H.

[0187] E4. A compound or pharmaceutically acceptable salt according to any one of embodiments E1-E2, wherein

[0188] R1 and R3 are the same C 1-6 Alkyl; and

[0189] R2 and R4 are the same C 1-6 alkyl.

[0190] E5. A compound or pharmaceutically acceptable salt according to any one of Embodiments E1-E2, wherein

[0191] R1 and R3 are both H and R2 and R4 are both methyl or both ethyl; or

[0192] R1 and R3 are both methyl or both ethyl and R2 and R4 are both H.

[0193] E6. A compound or pharmaceutically acceptable salt according to any one of embodiments E1-E2, wherein

[0194] R1 and R3 are both ethyl or both methyl; and

[0195] R2 and R4 are both ethyl or both methyl.

[0196] E7. The compound according to embodiment E1, wherein the compound is selected from the group consisting of:

[0197] Compound (1): (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(methylcarbamate)

[0198] Compound (2): (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(ethylcarbamate); and

[0199] Compound (3): (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(dimethylcarbamate);

[0200] or a pharmaceutically acceptable salt of any of these compounds.

[0201] E8. A compound which is a prodrug of compound (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (Compound (I)), wherein the prodrug provides a PK profile wherein when the prodrug is orally administered to Wistar rats at a dose corresponding to 287 μg / kg of (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, the C max between 25 and 200 pg / mL, such as between 50 and 150 pg / mL, such as between 50 and 100 pg / mL;

[0202] or a pharmaceutically acceptable salt of the compound.

[0203] E9. A compound according to embodiment E8 or a pharmaceutically acceptable salt thereof, which is a prodrug of compound (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (Compound (I)), wherein the prodrug provides a PK profile wherein when the prodrug is orally administered to Wistar rats at a dose corresponding to 287 μg / kg of (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, the AUC of (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol is 0.05. 0-24 Greater than 1000pg*h / mL.

[0204] E10. The compound according to any one of embodiments E8-E9 or a pharmaceutically acceptable salt thereof, wherein the PK profile has been obtained by a PK experiment as described in Example 3 herein.

[0205] E11. A compound according to any one of Embodiments E1-E10, or a pharmaceutically acceptable salt thereof, for use in therapy.

[0206] E12. A compound according to any one of embodiments E1-E10, or a pharmaceutically acceptable salt thereof, for use as a medicament.

[0207] E13. The compound or pharmaceutically acceptable salt according to embodiment E12 for use as a medicament, wherein the medicament is an oral medicament, such as a tablet or capsule for oral administration.

[0208] E14. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of embodiments E1-E10 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0209] E15. The pharmaceutical composition according to embodiment E14, wherein said pharmaceutical composition is for oral administration.

[0210] E16. The pharmaceutical composition according to any one of embodiments E14-E15, wherein the pharmaceutical composition is an oral pharmaceutical composition.

[0211] E17. The pharmaceutical composition according to any one of embodiments E14-E16, wherein the pharmaceutical composition is a solid oral dosage form.

[0212] E18. The pharmaceutical composition according to any one of embodiments E14-E17, wherein the pharmaceutical composition is a tablet or capsule for oral administration.

[0213] E19. The pharmaceutical composition according to any one of embodiments E14-E18, wherein the pharmaceutical composition further comprises another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease.

[0214] E20. A pharmaceutical composition according to any one of embodiments E14-E19, wherein the pharmaceutical composition further comprises a compound selected from the group consisting of: L-DOPA, droxidopa, foliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole; or antibodies targeting alpha-synuclein, tau protein or A-beta protein.

[0215] E21. A compound according to any one of embodiments E1-E10, or a pharmaceutically acceptable salt thereof, for use in treating a neurodegenerative disease or disorder such as Parkinson's disease, Huntington's disease, restless leg syndrome or Alzheimer's disease; or for use in treating a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

[0216] E22. A compound according to any one of embodiments E1-E10, or a pharmaceutically acceptable salt thereof, for use in the treatment according to embodiment E21, wherein the neurodegenerative disease or disorder is Parkinson's disease.

[0217] E23. A compound according to any one of embodiments E1-E10, or a pharmaceutically acceptable salt thereof, for use in the treatment according to any one of embodiments E21-E22, wherein the compound is to be used in combination with another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease.

[0218] E24. A compound according to any one of embodiments E1-E10, or a pharmaceutically acceptable salt thereof, for use in the treatment according to any one of embodiments E21-E23, wherein the compound is to be used in combination with a compound selected from the group consisting of L-DOPA, droxidopa, folliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole; or to be used in combination with an antibody targeting alpha-synuclein, tau protein or A-beta protein.

[0219] E25. A compound according to any one of embodiments E1-E10, or a pharmaceutically acceptable salt thereof, for use in the treatment according to any one of embodiments E21-E24, wherein the treatment is performed by oral administration of the compound.

[0220] E26. A compound according to any one of embodiments E1-E10, or a pharmaceutically acceptable salt thereof, for use in the treatment according to any one of embodiments E21-E25, wherein the compound is contained in an oral pharmaceutical composition such as a tablet or capsule for oral administration.

[0221] E27. A method for treating a neurodegenerative disease or disorder such as Parkinson's disease, Huntington's disease, restless leg syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction; the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of Examples E1-E10 or a pharmaceutically acceptable salt thereof.

[0222] E28. The method according to embodiment E27, wherein the neurodegenerative disease or disorder is Parkinson's disease.

[0223] E29. The method according to any one of embodiments E27-E28, wherein the compound according to any one of embodiments E1-E10 or a pharmaceutically acceptable salt thereof is used in combination with another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease.

[0224] E30. The method according to any one of embodiments E27-E29, wherein the compound according to any one of embodiments E1-E10 or a pharmaceutically acceptable salt thereof is used in combination with a compound selected from the group consisting of: L-DOPA, droxidopa, foliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole; or in combination with antibodies targeting alpha-synuclein, tau protein or A-beta protein.

[0225] E31. The method according to any one of embodiments E27-E30, wherein said administration is by oral route.

[0226] E32. The method according to any one of embodiments E27-E31, wherein the compound according to any one of embodiments E1-E10 or a pharmaceutically acceptable salt thereof is contained in an oral pharmaceutical composition such as a tablet or capsule for oral administration.

[0227] E33. Use of a compound according to any one of embodiments E1-E10 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder such as Parkinson's disease, Huntington's disease, restless leg syndrome or Alzheimer's disease; or for the treatment of a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

[0228] E34. The use according to embodiment E33, wherein the neurodegenerative disease or disorder is Parkinson's disease.

[0229] E35. The use according to any one of embodiments E33-E34, wherein the agent is used in combination with another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease.

[0230] E36. The use according to any one of embodiments E33-E35, wherein the agent is used in combination with a compound selected from the group consisting of: L-DOPA, droxidopa, foliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole; or in combination with antibodies targeting alpha-synuclein, tau protein or A-beta protein.

[0231] E37. The use according to any one of embodiments E33-E36, wherein the medicament is an oral medicament, such as a tablet or capsule for oral administration.

[0232] Other Embodiments of the Invention

[0233] The following sections further describe embodiments and aspects of the present invention. The first embodiment is denoted as EE1, the second embodiment is denoted as EE2, and so on.

[0234] EE1. A compound according to formula (Ie)

[0235]

[0236] wherein Y is selected from H and a carbamoyl group having the formula (CONR1R2)

[0237]

[0238] (CONR1R2),

[0239] and wherein X is selected from H and a carbamoyl group having the formula (CONR3R4)

[0240]

[0241] (CONR3R4), and

[0242] where Y and X are not both H, and

[0243] wherein R1, R2, R3 and R4 are each independently selected from the group consisting of: H, C 1-6 Alkyl, amino acid, amino acid residue, and peptide;

[0244] or a pharmaceutically acceptable salt thereof.

[0245] EE2. A compound or a pharmaceutically acceptable salt according to embodiment EE1, wherein

[0246] Y is a carbamoyl group having the formula (CONR1R2), and

[0247] X is H.

[0248] EE3. A compound or a pharmaceutically acceptable salt according to embodiment EE1, wherein

[0249] Y is H, and

[0250] X is a carbamoyl group having the formula (CONR3R4).

[0251] EE4. A compound or a pharmaceutically acceptable salt according to embodiment EE1, wherein

[0252] Y is a carbamoyl group having the formula (CONR1R2), and

[0253] X is a carbamoyl group having the formula (CONR3R4).

[0254] EE5. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE4, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide.

[0255] EE6. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE5, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein the amino acid, amino acid residue or peptide has an L-conformation.

[0256] EE7. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to an amino acid backbone atom of the amino acid, amino acid residue or peptide.

[0257] EE8. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the Cα atom of the amino acid, amino acid residue or peptide.

[0258] EE9. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the backbone carbonyl of the amino acid, amino acid residue or peptide.

[0259] EE10. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to a side chain atom of the amino acid, amino acid residue or peptide.

[0260] EE11. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the Cβ atom of the amino acid, amino acid residue or peptide.

[0261] EE12. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the Cγ side chain atom of the amino acid, amino acid residue or peptide.

[0262] EE13. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the Cδ side chain atom of the amino acid, amino acid residue or peptide.

[0263] EE14. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the Cε side chain atom of the amino acid, amino acid residue or peptide.

[0264] EE15. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the Cζ side chain atom of the amino acid, amino acid residue or peptide.

[0265] EE16. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the side chain oxygen atom of the amino acid, amino acid residue or peptide.

[0266] EE17. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the side chain nitrogen atom of the amino acid, amino acid residue or peptide.

[0267] EE18. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE6, wherein at least one of R1, R2, R3 and R4 is an amino acid, an amino acid residue or a peptide, and wherein N is attached to the side chain sulfur atom of the amino acid, amino acid residue or peptide.

[0268] EE19. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE18, wherein

[0269] R1 and R3 are both H, and

[0270] At least one of R2 and R4 is an amino acid, an amino acid residue or a peptide; or

[0271] Where R2 and R4 are both H, and

[0272] At least one of R1 and R3 is an amino acid, an amino acid residue or a peptide.

[0273] EE20.EE23. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE18, wherein

[0274] R1 and R3 are both H, and

[0275] Only one of R2 and R4 is an amino acid, an amino acid residue or a peptide; or

[0276] Where R2 and R4 are both H, and

[0277] Only one of R1 and R3 is an amino acid, an amino acid residue or a peptide.

[0278] EE21. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE18, wherein

[0279] R1 and R3 are both H, and

[0280] One of R2 and R4 is an amino acid, an amino acid residue or a peptide, and

[0281] One of R2 and R4 is H; or

[0282] Where R2 and R4 are both H, and

[0283] One of R1 and R3 is an amino acid, an amino acid residue or a peptide, and

[0284] One of R1 and R3 is H.

[0285] EE22. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE21, wherein R1, R2 and R3 are H, and

[0286] R4 is an amino acid, an amino acid residue or a peptide.

[0287] EE23. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-21, wherein

[0288] R1, R2 and R4 are H, and

[0289] R3 is an amino acid, an amino acid residue or a peptide.

[0290] EE24. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE21, wherein

[0291] R1, R3 and R4 are H, and

[0292] R2 is an amino acid, an amino acid residue or a peptide.

[0293] EE25. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE21, wherein

[0294] R2, R3 and R4 are H, and

[0295] R1 is an amino acid, an amino acid residue or a peptide.

[0296] EE26. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE21, wherein R1 is an amino acid residue.

[0297] EE27. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE26, wherein R2 is an amino acid residue.

[0298] EE28. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE27, wherein R3 is an amino acid residue.

[0299] EE29. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE28, wherein R4 is an amino acid residue.

[0300] EE30. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE21, wherein

[0301] R1 and R3 are both H, and wherein at least one of R2 and R4 is an amino acid residue; or wherein

[0302] R2 and R4 are both H, and wherein at least one of R1 and R3 is an amino acid residue.

[0303] EE31. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE2, EE7-EE21, wherein

[0304] R1 and R3 are both H, and wherein one of R2 and R4 is an amino acid residue, and wherein one of R2 and R4 is H; or wherein

[0305] R2 and R4 are both H, and wherein one of R1 and R3 is an amino acid residue, and wherein one of R1 and R3 is H.

[0306] EE32. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE31, wherein the amino acid is selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, glutamine, asparagine, histidine, serine, threonine, tyrosine, cysteine, tryptophan, methionine, alanine, isoleucine, leucine, phenylalanine, valine, proline and glycine.

[0307] EE33. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE32, wherein the amino acid residue is selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, glutamine, asparagine, histidine, serine, threonine, tyrosine, cysteine, tryptophan, methionine, alanine, isoleucine, leucine, phenylalanine, valine, proline and glycine.

[0308] EE34. The compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE33, wherein the amino acid residue is selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine.

[0309] EE35. The compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE34, wherein the amino acid residue is selected from the group consisting of phenylalanine and glycine.

[0310] EE36. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE25, wherein

[0311] R1 and R3 are both H, and wherein at least one of R2 and R4 is a peptide; or wherein R2 and R4 are both H, and wherein at least one of R1 and R3 is a peptide.

[0312] EE37. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE25, wherein

[0313] R1 and R3 are both H, and wherein one of R2 and R4 is a peptide, and wherein one of R2 and R4 is H; or wherein

[0314] R2 and R4 are both H, and wherein one of R1 and R3 is a peptide, and wherein one of R1 and R3 is H.

[0315] EE38. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE25, wherein

[0316] R2, R3 and R4 are H, and

[0317] R1 is a peptide.

[0318] EE39. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE25, wherein

[0319] R1, R3 and R4 are H, and

[0320] R2 is a peptide.

[0321] EE40. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE25, wherein

[0322] R1, R2 and R4 are H, and

[0323] R3 is a peptide.

[0324] EE41. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE25, wherein

[0325] R1, R2 and R3 are H, and

[0326] R4 is a peptide.

[0327] EE42. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE25 and EE36-EE41, wherein the peptide is a dipeptide, a tripeptide, or a derivative of a dipeptide or a tripeptide.

[0328] EE43. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE25 and EE36-EE42, wherein the peptide comprises two or more amino acid residues selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, glutamine, asparagine, histidine, serine, threonine, tyrosine, cysteine, tryptophan, methionine, alanine, isoleucine, leucine, phenylalanine, valine, proline and glycine residues.

[0329] EE44. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE25 and EE36-EE43, wherein the peptide comprises or consists of two or more amino acids selected from the group consisting of phenylalanine, valine, leucine, isoleucine, glycine and alanine.

[0330] EE45. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE25 and EE36-EE44, wherein the peptide comprises or consists of two or more L-amino acids.

[0331] EE46. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE25 and EE36-EE45, wherein the peptide is a dipeptide.

[0332] EE47. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE2 and EE36-EE46, wherein the peptide is a tripeptide.

[0333] EE48. The compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE25 and EE36-EE47, wherein the peptide comprises one or more amino acid residues selected from the group consisting of phenylalanine and glycine.

[0334] EE49. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE25 and EE36-EE48, wherein the peptide is a dipeptide comprising one or more amino acid residues selected from the group consisting of phenylalanine and glycine.

[0335] EE50. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE35, wherein

[0336] One of R1, R2, R3 and R4 is a glycine residue.

[0337] EE51. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE35 and EE50, wherein

[0338] One of R1, R2, R3 and R4 is a glycine residue, and three of R1, R2, R3 and R4 are H.

[0339] EE52. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE35 and EE50-EE51, wherein

[0340] One of R1, R2, R3 and R4 is CH2COOH.

[0341] EE53. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1-EE35 and EE50-EE52, wherein one of R1, R2, R3 and R4 is CH2COOH, and three of R1, R2, R3 and R4 are H.

[0342] EE54. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE35, EE50 and EE52, wherein

[0343] One of R1, R2, R3 and R4 is a phenylalanine residue.

[0344] EE55. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1-EE35 and EE54, wherein

[0345] One of R1, R2, R3 and R4 is a phenylalanine residue, and three of R1, R2, R3 and R4 are H.

[0346] EE56. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1, EE2 and EE4, wherein

[0347] R1 is H and R2 is C 1-6 Alkyl; or

[0348] R1 is C 1-6 Alkyl and R2 is H.

[0349] EE57. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1, EE2 and EE4, wherein R1 and R2 are the same C 1-6 alkyl.

[0350] EE58. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1, EE2 and EE4, wherein

[0351] R1 is H and R2 is methyl or ethyl; or

[0352] R1 is methyl or ethyl and R2 is H.

[0353] EE59. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1, EE2 and EE4, wherein R1 and R2 are independently selected from methyl and ethyl.

[0354] EE60. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1, EE2 and EE4, wherein R1 and R2 are both methyl.

[0355] EE61. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1, EE2 and EE4, wherein R1 and R2 are both ethyl.

[0356] EE62. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1, EE3 and EE4, wherein

[0357] R3 is H and R4 is C 1-6 Alkyl; or

[0358] R3 is C 1-6 Alkyl and R4 is H.

[0359] EE63. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1, EE3 and EE4, wherein R3 and R4 are the same C 1-6 alkyl.

[0360] EE64. A compound or a pharmaceutically acceptable salt according to any one of embodiments EE1, EE3 and EE4, wherein

[0361] R3 is H and R4 is methyl or ethyl; or

[0362] R3 is methyl or ethyl and R4 is H.

[0363] EE65. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1, EE3 and EE4, wherein R3 and R4 are independently selected from methyl and ethyl.

[0364] EE66. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1, EE3 and EE4, wherein R3 and R4 are both methyl.

[0365] EE67. A compound or pharmaceutically acceptable salt according to any one of embodiments EE1, EE3 and EE4, wherein R3 and R4 are both ethyl.

[0366] EE68. A compound or a pharmaceutically acceptable salt according to embodiments EE1 and EE4, wherein the compound has the following formula (Id):

[0367]

[0368] wherein R1, R2, R3 and R4 are each independently selected from the group consisting of: H, C 1-6 Alkyl, amino acid, amino acid residue, and peptide;

[0369] or a pharmaceutically acceptable salt thereof.

[0370] EE69. A compound or pharmaceutically acceptable salt according to embodiment EE68, wherein R1, R2, R3 and R4 are each independently selected from the group consisting of: H, linear C 1-6 Alkyl, amino acid, amino acid residue and peptide.

[0371] EE70. A compound or a pharmaceutically acceptable salt according to embodiments EE68-EE69, wherein

[0372] R1=R3 and R2=R4.

[0373] EE71. A compound or a pharmaceutically acceptable salt according to embodiments EE68-EE70, wherein

[0374] R1 and R3 are both H and R2 and R4 are the same C 1-6 Alkyl; or

[0375] R1 and R3 are the same C 1-6 Alkyl and R2 and R4 are both H.

[0376] EE72. A compound or a pharmaceutically acceptable salt according to embodiments EE68-EE71, wherein

[0377] R1 and R3 are the same C 1-6 Alkyl; and

[0378] R2 and R4 are the same C 1-6 alkyl.

[0379] EE73. A compound or a pharmaceutically acceptable salt according to embodiments EE68-EE72, wherein

[0380] R1 and R3 are the same straight chain C 1-6 Alkyl; and

[0381] R2 and R4 are the same straight chain C 1-6 alkyl.

[0382] EE74. A compound or a pharmaceutically acceptable salt according to embodiments EE68-EE71, wherein

[0383] R1 and R3 are both H and R2 and R4 are both methyl or both ethyl; or

[0384] R1 and R3 are both methyl or both ethyl and R2 and R4 are both H.

[0385] EE75. A compound or a pharmaceutically acceptable salt according to embodiments EE68-EE73, wherein

[0386] R1 and R3 are both ethyl or both methyl; and R2 and R4 are both ethyl or both methyl.

[0387] EE76. A compound according to embodiment EE1, wherein the compound is selected from the group consisting of:

[0388] Compound (1): (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(methylcarbamate)

[0389] Compound (2): (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(ethylcarbamate); and

[0390] Compound (3): (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(dimethylcarbamate);

[0391] Compound (4): ((((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)carbonyl)glycine;

[0392] Compound (5): ((((4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl)oxy)carbonyl)glycine;

[0393] Compound (6): (S)-2-amino-3-(3-(((((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)carbonyl)amino)phenyl)propanoic acid and a pharmaceutically acceptable salt of any of these compounds.

[0394] EE77. A compound according to embodiment EE1, wherein the compound is selected from the group consisting of:

[0395] Compound (1): (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(methylcarbamate)

[0396] Compound (2): (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(ethylcarbamate); and

[0397] Compound (3): (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(dimethylcarbamate);

[0398] and pharmaceutically acceptable salts of any of these compounds.

[0399] EE78. A compound according to any one of embodiments EE1-EE77, or a pharmaceutically acceptable salt thereof, for use in therapy.

[0400] EE79. A compound according to any one of embodiments EE1-EE77 or a pharmaceutically acceptable salt thereof for use as a medicament.

[0401] EE80. The compound or pharmaceutically acceptable salt according to EE79 for use as a medicament, wherein the medicament is an oral medicament, such as a tablet or capsule for oral administration.

[0402] EE81. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of embodiments EE1-EE77 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0403] EE82. A pharmaceutical composition according to embodiment EE81, wherein the pharmaceutical composition is for oral administration.

[0404] EE83. A pharmaceutical composition according to any one of embodiments EE81-EE82, wherein the pharmaceutical composition is an oral pharmaceutical composition.

[0405] EE84. A pharmaceutical composition according to any one of embodiments EE81-EE83, wherein the pharmaceutical composition is a solid oral dosage form.

[0406] EE85. A pharmaceutical composition according to any one of embodiments EE81-EE84, wherein the pharmaceutical composition is a tablet or capsule for oral administration.

[0407] EE86. A pharmaceutical composition according to any one of embodiments EE81-EE85, wherein the pharmaceutical composition further comprises another agent that can be used to treat a neurodegenerative disease or disorder, such as Parkinson's disease.

[0408] EE87. A pharmaceutical composition according to any one of embodiments EE81-EE86, wherein the pharmaceutical composition further comprises a compound selected from the group consisting of: L-DOPA, droxidopa, foliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole; or antibodies targeting α-synuclein, tau protein or A-β protein.

[0409] EE88. A compound according to any one of embodiments EE1-EE77 or a pharmaceutically acceptable salt thereof, for use in treating a neurodegenerative disease or disorder such as Parkinson's disease, Huntington's disease, restless leg syndrome or Alzheimer's disease; or for use in treating a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

[0410] EE89. A compound according to any one of embodiments EE1-EE77, or a pharmaceutically acceptable salt thereof, for use in the treatment according to embodiment EE88, wherein the neurodegenerative disease or disorder is Parkinson's disease.

[0411] EE90. A compound according to any one of embodiments EE1-EE77, or a pharmaceutically acceptable salt thereof, for use in the treatment according to any one of embodiments EE88-EE89, wherein the compound is to be used in combination with another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease.

[0412] EE91. A compound according to any one of embodiments EE1-EE77, or a pharmaceutically acceptable salt thereof, for use in the treatment according to any one of embodiments EE88-EE90, wherein the compound is to be used in combination with a compound selected from the group consisting of L-DOPA, droxidopa, foliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole; or to be used in combination with an antibody targeting alpha-synuclein, tau protein or A-beta protein.

[0413] EE92. A compound according to any one of embodiments EE1-EE77, or a pharmaceutically acceptable salt thereof, for use in the treatment according to any one of embodiments EE88-EE90, wherein the treatment is performed by oral administration of the compound.

[0414] EE93. A compound according to any one of embodiments EE1-EE77, or a pharmaceutically acceptable salt thereof, for use in the treatment according to any one of embodiments EE88-EE92, wherein the compound is contained in an oral pharmaceutical composition, such as a tablet or capsule for oral administration.

[0415] EE94. A method for treating a neurodegenerative disease or disorder such as Parkinson's disease, Huntington's disease, restless leg syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction; the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of Examples EE1-EE77 or a pharmaceutically acceptable salt thereof.

[0416] EE95. A method according to embodiment EE94, wherein the neurodegenerative disease or disorder is Parkinson's disease.

[0417] EE96. The method according to any one of embodiments EE94-EE95, wherein the compound according to any one of embodiments EE1-EE77 or a pharmaceutically acceptable salt thereof is used in combination with another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease.

[0418] EE97. A method according to any one of embodiments EE94-EE96, wherein the compound according to any one of embodiments EE1-EE77 or a pharmaceutically acceptable salt thereof is used in combination with a compound selected from the group consisting of: L-DOPA, droxidopa, foliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole; or in combination with antibodies targeting alpha-synuclein, tau protein or A-beta protein.

[0419] EE98. A method according to any one of embodiments EE94-EE97, wherein the administration is performed by oral route.

[0420] EE99. The method according to any one of embodiments EE94-EE98, wherein the compound according to any one of embodiments EE1-EE77 or a pharmaceutically acceptable salt thereof is contained in an oral pharmaceutical composition, such as a tablet or capsule for oral administration.

[0421] EE100. Use of a compound according to any one of embodiments EE1-EE77 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a neurodegenerative disease or disorder such as Parkinson's disease, Huntington's disease, restless leg syndrome or Alzheimer's disease; or for treating a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

[0422] EE101. The use according to embodiment EE100, wherein the neurodegenerative disease or disorder is Parkinson's disease.

[0423] EE102. The use according to any one of embodiments EE100-EE101, wherein the agent is used in combination with another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease.

[0424] EE103. The use according to any one of embodiments EE100-EE102, wherein the agent is used in combination with a compound selected from the group consisting of: L-DOPA, droxidopa, foliglurax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, anti-glutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or epiriprazole; or in combination with antibodies targeting α-synuclein, tau protein or A-β protein.

[0425] EE104. The use according to any one of embodiments EE100-EE103, wherein the medicament is an oral medicament, such as a tablet or capsule for oral administration.

[0426] All documents (including publications, patent applications, and patents) cited herein are hereby incorporated by reference in their entirety and to the same extent as if each document were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).

[0427] Headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.

[0428] Unless stated otherwise or clearly contradicted by context, descriptions of any aspect or aspects of the invention herein using terms such as “comprising,” “having,” “including,” or “containing” referring to one or more elements are intended to provide support for the similar aspect or aspects of the invention “consisting of,” “consisting essentially of,” or “consisting essentially of,” the specified one or more elements (e.g., a composition described herein as comprising a specified element is to be understood to also describe a composition consisting of that element, unless stated otherwise or clearly contradicted by context).

[0429] Unless otherwise indicated, any and all examples or exemplary language (including "for instance", "for example", "eg", and "as such") used in this specification are intended merely to better illuminate the invention and do not pose a limitation on the scope of the invention.

[0430] It should be understood that the various aspects, embodiments, implementations and features of the invention mentioned herein may be claimed individually or in any combination.

[0431] This invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.

[0432] Compounds of the present invention

[0433] Table 2: Exemplary compounds of the invention

[0434]

[0435]

[0436] Experimental Section

[0437] Preparation of the compounds of the present invention

[0438] Compounds with formula (Id) can be prepared by the method described below and synthetic methods known in the field of organic chemistry or modifications familiar to those of ordinary skill in the art. The starting material used in this article is commercially available or can be prepared by conventional methods known in the art, such as those described in standard reference books (such as "Compendium of Organic Synthetic Methods [Organic Synthesis Methods Compendium], Volumes I-XII" (Wiley International Science Company (Wiley-Interscience) publishes)). Preferred methods include but are not limited to those described below.

[0439] These schemes are representative of methods that can be used to synthesize the compounds of the present invention. They are not intended to limit the scope of the present invention in any way.

[0440] List of abbreviations for chemical compounds

[0441] BF3-OEt2: Boron trifluoride etherate

[0442] BnBr: benzyl bromide

[0443] BnCl: benzyl chloride

[0444] DCM: dichloromethane

[0445] DMF: dimethylformamide

[0446] ee: enantiomeric excess

[0447] EtOAc: Ethyl acetate

[0448] MeCN: Acetonitrile

[0449] MeOH: Methanol

[0450] MeI: methyl iodide

[0451] MOM-Cl: Chloromethyl methyl ether

[0452] Pd / C: Palladium on carbon

[0453] Pyridine-HF: Pyridine hydrofluoride

[0454] TBAF: Tetrabutylammonium fluoride

[0455] TFA: trifluoroacetic acid

[0456] TMS-I: Trimethylsilyl iodide

[0457] LC-MS method

[0458] Analytical LC-MS data were obtained using the methods identified below unless otherwise described in detail in the experimental protocols below.

[0459] Method 550:

[0460] LC-MS was run on a Waters Aquity UPLC-MS consisting of a Waters Aquity including a column manager, a binary solvent manager, a sample organizer, a PDA detector (operating at 254 nM), an ELS detector, and a TQ-MS equipped with an APPI source operating in positive ion mode.

[0461] LC-conditions: The column was Acquity UPLC BEH C18 1.7 μm; 2.1 x 50 mm, operated at 60°C with a binary gradient consisting of water + 0.05% trifluoroacetic acid (A) and acetonitrile / water (95:5) + 0.05% trifluoroacetic acid at 1.2 ml / min.

[0462] gradient:

[0463]

[0464] Total running time: 1.15 minutes

[0465] Method 10-90AB (LC-20AD & MS 2010 from Shimadzu):

[0466]

[0467]

[0468] LC-conditions: The column was Luna-C18 (2) 2.0*30 mm, (3 micron particles), operated at 40°C with a gradient of water + 0.037% TFA (A) and MeCN + 0.018% TFA (B) at 0.8 mL / min (0.01-1.51 min) and 1.2 mL / min (1.52-2.00 min).

[0469] gradient:

[0470]

[0471] Total running time: 2.00min

[0472] LC-MS Method B:

[0473] LC-MS was run on an Agilent 1260 HPLC consisting of column assembly, binary pump, Hip sample, and single Q-MS equipped with an ESI source operating in positive ion mode.

[0474] LC-conditions: Column: Inertsustain AQ-C18 HP 3.0 μm; 3.0 x 50 mm, operated at 35°C with a binary gradient consisting of water + 0.05% trifluoroacetic acid (A) and acetonitrile + 0.05% trifluoroacetic acid (B) at 1.2 ml / min.

[0475] gradient:

[0476] 0.00min 0%B

[0477] 3.00min 95%B

[0478] 4.00min 95%B

[0479] Total running time: 4.0 minutes

[0480] General scheme for preparing compounds (1) to (3) of the present invention

[0481] (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol hydrochloride [Compound (I)] (which can be prepared, for example, as disclosed in WO 2009 / 026934) was used as a substrate to synthesize compounds (1)-(3) of the present invention according to the following scheme.

[0482]

[0483] Prodrugs bearing two identical carbamate groups can be prepared by treating compound (I) with a carbamoyl chloride such as N,N-dimethylcarbamoyl chloride in the presence of a base such as triethylamine or K2CO3, as described for (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diylbis(dimethylcarbamate). Compound (I) can be reacted with an isocyanate such as ethyl isocyanate and a suitable base such as triethylamine or K2CO3, as described for (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diylbis(ethylcarbamate).

[0484]

[0485] Prodrugs in which only one of the catechol hydroxyl groups is alkylated can be prepared from compounds like (4aR, 10aR)-7-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol (Compound A2) or (4aR, 10aR)-7-methoxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol (Compound A6) by treatment with carbamoyl chloride or isocyanate in the presence or absence of a suitable base like triethylamine, diethyl-isopropylamine or potassium carbonate. In these reactions, Compounds A2 and A6 can be used in their free form or as acid addition salts such as hydrogen iodide (A2-HI), hydrogen bromide or hydrogen chloride salts. The synthesis of both precursors is described herein. The opposite regioisomer can be prepared in a similar manner from (4aR,10aR)-6-methoxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ol or (4aR,10aR)-6-benzyloxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ol.

[0486]

[0487] Treatment of compound (I) with BnCl and a base such as triethylamine or K2CO3 will give a mixture of (4aR,10aR)-6-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ol and (4aR,10aR)-7-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol; these regioisomers can be separated. Using MeI instead of BnCl will provide a mixture of the corresponding methyl ethers, which can be separated.

[0488]

[0489] Provided herein are selective pathways to (4aR,10aR)-7-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol and (4aR,10aR)-7-methoxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol.

[0490] (4aR,10aR)-6-methoxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ol can be prepared from (4aR,10aR)-7-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol by methylation followed by debenzylation or by using the MOM-based protecting group strategy for the synthesis of (4aR,10aR)-7-methoxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol.

[0491]

[0492] An alternative route to (4aR,10aR)-6-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ol can be based on treatment of (4aR,10aR)-1-propyl-7-((triisopropylsilyl)oxy)-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol with 2,2,2-trichloroacetimidylbenzyl ester in the presence of a suitable Lewis acid like BF3-OEt2, followed by cleavage of the silyl protecting group with KOH, TBAF or pyridine-HF.

[0493]

[0494] Intermediates of the present invention

[0495]

[0496] A1: (4aR, 10aR)-6,7-bis(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinone Phytophenone

[0497] The hydrochloride (10.75g) and K of compound (I) are loaded into a single-necked 1L round-bottomed flask with a magnetic stirring bar CO (17.5g). The flask is evacuated and backfilled with nitrogen, followed by introduction of dry DMF (107mL). Subsequently, benzyl chloride (8.55mL) is added and the mixture is stirred at room temperature for 18 hours, then warmed to 100 ° C for 5 hours, and then cooled to room temperature and stirred for another 19 hours. Subsequently, additional K CO (7.48g) and benzyl chloride (6.29mL) are added, and the mixture is stirred at 100 ° C for 5 hours. Then, the mixture is cooled to room temperature and water (500mL) and heptane (250mL) are added. The aqueous phase is extracted with heptane (3x100mL), and the organic phase combined is washed with brine (100mL), dried over sodium sulfate, filtered and concentrated to obtain title compound (14.6g).

[0498] A2-HI: (4aR,10aR)-7-(Benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline Phylin-6-ol Hydroiodide

[0499] A magnetic stirring bar and (4aR, 10aR)-6,7-bis(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline (11.9 g) were loaded into a 1L single-necked round-bottom flask. A rubber stopper was placed in a flask, and the flask was evacuated and backfilled with nitrogen. MeCN (180 mL) was added and the mixture was stirred until all starting materials dissolved. TMS-I (10.0 mL) was added and the mixture was stirred at room temperature for 2 hours. Then, MeOH (5.5 mL) was added and the mixture was stirred for 1 hour. Subsequently, 1:15 (v / v) isopropyl acetate / heptane (160 mL) was added and the mixture was cooled (ice bath) and stirred for 60 minutes. The precipitate was filtered out and washed with 1:15 (v / v) isopropyl acetate / heptane (1x 50 mL). The solid was dried to obtain the title compound (7.6 g).

[0500] LCMS (Method 550), retention time = 0.55 min, [M+H] + =352.5.

[0501] 1 H NMR (600MHz, CDCl3) δ10.42(bs,1H),7.43-7.33(m,4H),7.26(d,J=1.0Hz,1H),6.78(d,J=8.3Hz,1H),6.58(d,J=8.3Hz,1H),5.72(s,1H),5.08(s, 2H),3.71(dd,J=11.70,15.0Hz,1H),3.58(d,J=11.70,1H),3.25-3.11(m ,4H),2.94-2.86(m,1H),2.77-2.57(m,2H),2.26(dd,J=11.70Hz,17.0Hz 1H), 2.19 (d, J = 13.80, 1H), 2.01-1.92 (m, 2H), 1.80-1.69 (m, 1H), 1.56-1.53 ​​(m, 1H), 1.39 (qd, J = 3.60Hz, 13.30Hz, 1H), 1.06 (t, J = 7.2Hz, 3H).

[0502]

[0503] A3: (4aR, 10aR)-7-(benzyloxy)-6-(methoxymethoxy)-1-propyl-1,2,3,4,4a,5,10,10a- Octahydrobenzo[g]quinoline

[0504] To a mixture of (4aR, 10aR) -7- (benzyloxy) -1-propyl -1,2,3,4,4a,5,10,10a- octahydrobenzo [g] quinolin-6-ol (20 g) in DMF (400 mL) was slowly added NaH (4.17 g, 60% dispersion) at 0 ° C. The mixture was stirred at 0 ° C for 30 minutes. Then MOMCl (3.5 mL) was added dropwise at 0 ° C. The mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water (400 mL) and stirred for 20 minutes. The aqueous phase was extracted with EtOAc (300 mL × 3). The combined organic layers were washed with brine (500 mL), dried over sodium sulfate, filtered and concentrated to give the title compound (20 g).

[0505] LCMS (Method 10-90AB), retention time = 0.90 min, [M+H] + =396.3.

[0506] A4: (4aR,10aR)-6-(methoxymethoxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g] Quinolin-7-ol

[0507] To a solution of (4aR,10aR)-7-(benzyloxy)-6-(methoxymethoxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline (20 g) in MeOH (140 mL) was added 10% Pd / C (30 g) under N2. The suspension was degassed and purged with H2. The mixture was stirred at 25 °C under H2 (50 psi) for 12 h. The reaction mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure to give the title compound (15.4 g).

[0508] LCMS (Method 10-90AB), retention time = 0.65 min, [M+H] + =306.1.

[0509] A5: (4aR, 10aR)-7-methoxy-6-(methoxymethoxy)-1-propyl-1,2,3,4,4a,5,10,10a-octadecyl Hydrobenzo[g]quinoline

[0510] To a solution of (4aR,10aR)-6-(methoxymethoxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ol (15 g) in MeOH (150 mL) was added trimethylsilyl)diazomethane (TMSCH2N2; 2M in hexanes, 246 mL) dropwise over 0.5 h at 20° C. The mixture was concentrated to give the title compound (15 g).

[0511] A6: (4aR, 10aR)-7-methoxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6- alcohol

[0512] (4aR, 10aR) -7-methoxy -6- (methoxymethoxy) -1- propyl -1,2,3,4,4a,5,10,10a- octahydrobenzo [g] quinoline (15g) and 4M HCl in MeOH (150mL) were loaded into a reactor (100mL) at 20°C. The reaction mixture was stirred at 20°C for 1 hour and then concentrated. The residue was dissolved in water (100mL) and the aqueous layer was basified to pH 7-8 with sodium bicarbonate. The aqueous layer was extracted with EtOAc (100x 1mL, 50mL x 1). The organic layers were combined and washed with brine (100mL), dried over sodium sulfate, filtered and concentrated to provide the title compound (7g).

[0513] 1 H NMR(400MHz, CDCl3) δ6.70(d,J=8.4Hz,1H),6.62(d,J=8.0Hz,1H),5.71(brs,1H),3 .86(s,3H),3.07-3.18(m,2H),3.01(dd,J=5.2,17.6Hz,1H),2.72-2.89(m,2H),2.58 -2.68(m,1H),2.29-2.44(m,2H),2.24(dd,J=12.0,17.6Hz,1H),1.97(d,J=13.2Hz, 1H), 1.70-1.92 (m, 3H), 1.54-1.63 (m, 2H), 1.10-1.23 (m, 1H), 0.93 (t, J = 7.2Hz, 3H).

[0514] Preparation of Exemplary Compounds of the Present Invention from Compound (I)

[0515] Compound (1): (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7- Dimethyl bis(carbamate)

[0516]

[0517] (4aR, 10aR) -1-propyl- 1,2,3,4,4a,5,10,10a-octahydrobenzo [g] quinoline -6,7-diol hydrochloride (500 mg), ascorbic acid (30 mg) and 4- (dimethylamino) pyridine (11 mg) were weighed into a vial. DMF (5 mL) was added. The vial was evacuated and backfilled with nitrogen. Triethylamine (0.7 mL) and N, N- dimethylcarbamoyl chloride (0.39 mL) were added and the mixture was stirred at room temperature for 2 hours. Additional triethylamine (0.7 mL) and N, N- dimethylcarbamoyl chloride (0.6 mL) were then added and the mixture was stirred at room temperature for 1 hour. The mixture was purified by chromatography (EtOAc / heptane / triethylamine 20: 19: 1) to give the crude product. The material was dissolved in THF (20 mL) and cooled to 0 ° C. To the well stirred mixture was added 0.1 M HCl in THF dropwise until slightly acidic. A dense white precipitate gradually formed. The mixture was stirred on ice. The solid was collected and dried to give the title compound (233 mg) as the HCl salt.

[0518] 1 H NMR(600MHz,DMSO-d6)δ10.54(s,1H),7.05(s,2H),3.54-3.40(m,2H),3.32-3.26(m,1 H),3.26-3.18(m,1H),3.12-2.98(m,6H),2.95(s,3H),2.90(s,3H),2.89(s,3H),2.84( dd,J=17.3,4.9Hz,1H),2.25(dd,J=17.3,11.8Hz,1H),2.09-2.00(m,1H),2.00-1.88( m,2H),1.88-1.80(m,1H),1.79-1.61(m,2H),1.40-1.28(m,1H),0.96(t,J=7.4Hz,3H).

[0519] LCMS (Method 550_ESI): retention time = 0.42 min; UV-purity 100%; ELS-purity 100%; m / z = 404.5 [M+H] +.

[0520] Compound (2): (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7- Diethyl bis(ethyl carbamate)

[0521]

[0522] (4aR, 10aR) -1-propyl -1,2,3,4,4a,5,10,10a- octahydrobenzo [g] quinoline -6,7- diol hydrochloride (500 mg) and ascorbic acid (28 mg) were weighed into a vial followed by the addition of DMF (4.0 mL). The vial was evacuated and backfilled with nitrogen. Triethylamine (1 mL) and ethyl isocyanate (0.35 mL) were added and the mixture was stirred at room temperature for 2 hours. The mixture was poured into brine and extracted with EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by chromatography (EtOAc / heptane / triethylamine 10:9:1) to give a crude product. The material was dissolved in EtOAc (20 mL) and cooled to 0 ° C. 0.2 M HCl in EtOAc was added dropwise to the well-stirred mixture until pH 3-4. The white precipitate formed was collected and dried to give the title compound as an HCl salt (239 mg).

[0523] 1 H NMR (600MHz, DMSO-d6) δ10.52(brs,1H),7.78(t,J=5.6Hz,1H),7.70(t,J=5.6Hz,1H),7.02(d,J=8.4Hz,1H) ,6.98(d,J=8.4Hz,1H),3.48(d,J=12.1Hz,1H),3.42(dd,J=16.0,5.3Hz,1H),3.35-3.25(m,1H),3.26-3.18( m,1H),3.18-2.95(m,7H),2.78(dd,J=17.2,4.9Hz,1H),2.22(dd,J=17.2,11.9Hz,1H),2.10-1.89(m,3H),1 .87-1.80(m,1H),1.80-1.64(m,2H),1.34(qd,J=13.1,4.0Hz,1H),1.14-1.02(m,6H),0.96(t,J=7.3Hz,3H).

[0524] LCMS (Method 550): retention time = 0.41 min; UV-purity 100%; ELS-purity 98%; m / z = 404.6 [M+H] + .

[0525] Compound (3): (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7- Dimethyl bis(dimethylcarbamate)

[0526]

[0527] (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol hydrochloride (500 mg) and ascorbic acid (28 mg) were weighed into a vial followed by the addition of DMF (4.0 mL). The vial was evacuated and backfilled with nitrogen. Triethylamine (1.0 mL) and methyl isocyanate (0.21 mL) were added and the mixture was stirred at room temperature for 2 hours. The mixture was poured into brine and extracted with EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified by chromatography (EtOAc / heptane / triethylamine 14:5:1) to give a crude product. The material was dissolved in a hot mixture of THF (10 mL) and EtOAc (15 mL). Heptane (10 mL) was added and the mixture was concentrated to a volume of approximately 15 mL. The solution was cooled to 0°C to precipitate a solid, which was collected and dried to give the title compound (310 mg).

[0528] 1 H NMR(600MHz,DMSO-d6)δ7.63(q,J=4.6Hz,1H),7.57(q,J=4.6Hz,1H),6.97(d,J=8.3Hz,1H), 6.89(d,J=8.3Hz,1H),3.20(dd,J=16.3,4.9Hz,1H),2.91(d,J=11.2Hz,1H),2.77-2.58(m,8H ),2.52-2.43(m,1H),2.31(ddd,J=13.1,9.5,4.8Hz,1H),2.18-2.03(m,3H),1.85-1.77(m,1H ),1.65-1.58(m,1H),1.59-1.36(m,4H),1.04(qd,J=12.8,4.1Hz,1H),0.86(t,J=7.3Hz,3H).

[0529] LCMS (Method 550): retention time = 0.32 min; UV-purity 100%; ELS-purity 100%; m / z = 376.53 [M+H] + .

[0530] Compound (4): ((((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo [g]-quinolin-6-yl)oxy)carbonyl)glycine

[0531] Compound (4) can be prepared, for example, from the intermediate (4aR, 10aR)-7-(benzyloxy)-1-propyl-2H, 3H, 4H, 4aH, 5H, 10H, 10aH-benzo[g]quinolin-6-ol hydroiodide (Compound A2-HI) using a two-step process as described below:

[0532] Preparation of ((((4aR,10aR)-7-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)carbonyl)glycine benzyl ester (Compound A7)

[0533]

[0534] To a stirred solution of 2-aminoacetic acid benzyl hydrochloride (1.01 g, 5.0 mmol) and triphosgene (0.59 g, 2.0 mmol) in DCM (50 mL) was added Et3N (1.69 g, 16.7 mmol) at 0 ° C. The resulting mixture was stirred for 1 hour at 0 ° C. To the above mixture was added (4aR, 10aR) -7- (benzyloxy) -1- propyl -2H, 3H, 4H, 4aH, 5H, 10H, 10aH- benzo [g] quinoline -6- alcohol hydrogen iodide (2.00 g, 4.2 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water / ice (50 mL). The water layer was extracted with DCM (3x 50 mL). The combined organic extracts were concentrated. The residue was purified by reverse phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in water (0.05% TFA), gradient 0% to 75% over 30 minutes; detector, UV 220 nm to afford the title compound (2.1 g) in sufficient purity for the next step.

[0535] Preparation of ((((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)carbonyl)glycine (Compound (4)) from Compound (A7)

[0536]

[0537] To a solution of ((((4aR,10aR)-7-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)carbonyl)glycine benzyl ester (2.10 g, 3.9 mmol) in MeOH (100 mL) was added Pd(OH)2 / C (10%, 0.4 g) in a 250 mL round bottom flask under nitrogen atmosphere. The mixture was hydrogenated at room temperature for 2 h using a hydrogen balloon under hydrogen atmosphere, filtered through a pad of celite, and concentrated under reduced pressure. The residue was purified by trituration with EtOH (100 mL) to give the title compound (693 mg).

[0538] LC / MS: retention time: 1.35 min, UV-purification: 95.5%; (ES, m / z): [M+H]+363. Instrument: Shimadzu LCMS-2020 equipped with Shim-Pack XR-ODS C18, L=50 mm, D=3.0 mm column operated at 40°C. Mobile phase A: 0.05% TFA in water; Mobile phase B: 0.05% TFA in acetonitrile. Flow rate 1.2 mL / min.

[0539] gradient:

[0540] 0-3.2 minutes A:B 95:5;

[0541] 3.2min-3.7min: A:B 1:1;

[0542] 3.7min-4.75min: A:B 0:1;

[0543] 4.75min-5.0min:A:B 95:5.

[0544] 1H NMR (400MHz, DMSO) δ6.84-6.82(d,1H),6.73-6.71(d,1H),3.73-3.69(m,3H),3.52-3.49(d,1H),3.30-3.27(m,2H) ,2.85-2.79(m,2H),2.72-2.66(m,2H),2.32-2.22(m,1H),1.94-1.57(m,6H),1.32-1.27(m,1H),0.98-0.91(t,3H).

[0545] Compound (5): ((((4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo [g]-quinolin-7-yl)oxy)carbonyl)glycine

[0546] Compound (5) can be prepared, for example, from the intermediate (4aR, 10aR)-7-(benzyloxy)-1-propyl-2H, 3H, 4H, 4aH, 5H, 10H, 10aH-benzo[g]quinolin-6-ol hydroiodide, compound (A2-HI) using a four-step process as described below:

[0547] Preparation of (4aR,10aR)-7-(benzyloxy)-6-(methoxymethoxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline (Compound (A3))

[0548]

[0549] To a stirred solution of (4aR,10aR)-7-(benzyloxy)-1-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinolin-6-ol hydroiodide (5.00 g, 10.4 mmol) in DMF (100 mL) was added NaH (60% oil dispersion; 1.04 g, 26.0 mmol) portionwise at 0°C. The resulting mixture was stirred at 0°C under nitrogen atmosphere for 0.5 h. To the above mixture was added MOM-Cl (0.83 g, 12.4 mmol) dropwise at 0°C. The resulting mixture was stirred at 0°C for 2 h after which the reaction was quenched with water (300 mL). The resulting mixture was extracted with EtOAc (3 x 200 mL) and the combined organic extracts were concentrated. The residue was purified by reverse phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, in water (10 mM MeCN in NH4HCO3), gradient 0% to 80% in 40 min; detector, UV 220 nm, afforded the title compound (2.4 g) in sufficient purity for the next step.

[0550] Preparation of (4aR,10aR)-6-(methoxymethoxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ol (Compound (A4))

[0551]

[0552] To a solution of (4aR,10aR)-7-(benzyloxy)-6-(methoxymethoxy)-1-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinoline (2.40 g, 6.1 mmol) in MeOH (50 mL) was added Pd(OH)2 / C (0.5 g, 10%) under nitrogen. The mixture was hydrogenated overnight at room temperature using a hydrogen balloon under a hydrogen atmosphere. The crude mixture was filtered through a pad of celite and concentrated under reduced pressure to give the title compound (1.9 g) pure enough for the next step.

[0553] Preparation of ((((4aR,10aR)-1-ethyl-6-(methoxymethoxy)-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl)oxy)carbonyl)glycine tert-butyl ester (Compound (A8))

[0554]

[0555] To a stirred solution of tert-butyl 2-aminoacetate (0.52 g, 3.9 mmol) and triphosgene (0.47 g, 1.6 mmol) in DCM (30 mL) was added Et at 0 ° C. N (1.33 g, 13.1 mmol). The resulting mixture was stirred at 0 ° C for 1 hour, followed by addition of (4aR, 10aR) -6- (methoxymethoxy) -1- propyl -2H, 3H, 4H, 4aH, 5H, 10H, 10aH- benzo [g] quinoline -7- alcohol (1.00 g, 3.3 mmol). The resulting mixture was stirred at room temperature overnight, followed by quenching the reaction with water / ice (50 mL). The aqueous layer was extracted with DCM (3 x 50 mL), and the combined organic extracts were concentrated. The residue was purified by reverse phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in water (0.05% TFA), gradient 0% to 75% in 30 min; detector, UV 220 nm to afford the title compound (0.8 g) pure enough for the next step.

[0556] Preparation of ((((4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl)oxy)carbonyl)glycine (Compound (5)) from Compound (A8)

[0557]

[0558] To a stirred solution of ((((4aR,10aR)-1-ethyl-6-(methoxymethoxy)-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl)oxy)carbonyl)glycine tert-butyl ester (0.8 g, 1.7 mmol) in DCM (10 mL) was added TFA (3.0 mL). The resulting mixture was stirred at room temperature for 4 hours after which it was concentrated. The residue was purified by preparative HPLC under the following conditions (column: XBridge Shield RP18 OBD column, 19*250 mm, 10 um; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 12% B to 14% B 254 nm in 10 minutes) to give the title compound (225 mg).

[0559] LC / MS: retention time: 1.48 min, UV-purity: 97.3%; (es, m / z): [M+H] +363. Instrument: Shimadzu LCMS-2020 equipped with Shim-Pack XR-ODS C18, L=50 mm, D=3.0 mm column operated at 40°C. Mobile phase A: 0.05% TFA in water; Mobile phase B: 0.05% TFA in acetonitrile. Flow rate 1.2 mL / min. Gradient:

[0560] 0-3.2min A:B 95:5;

[0561] 3.2min-3.7min: A:B 1:1;

[0562] 3.7min-4.75min: A:B 0:1;

[0563] 4.75min-5.0min:A:B 95:5.

[0564] 1 H NMR (400MHz, DMSO) δ6.84-6.82(d,1H),6.73-6.71(d,1H),3.79(s,2H),3.64-3.52(d,1H),3.29-3.28(m,1H),3. 14-2.92(m,4H),2.80-2.72(m,2H),2.22-2.18(m,1H),1.94-1.57(m,6H),1.40-1.31(m,1H),0.98-0.94(t,3H).

[0565] Compound (6): (S)-2-amino-3-(3-(((((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5, 10,10a-Octahydrobenzo[g]quinolin-6-yl)oxy)carbonyl)amino)phenyl)propanoic acid

[0566] Compound (6) can be prepared, for example, from the intermediate (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3-nitrophenyl)propionic acid compound (A9) (commercially available from, for example, Nanjing Jing Peptide Biotechnology Co., Ltd.) using the five-step method described below:

[0567] Preparation of (S)-2-((tert-butoxycarbonyl)amino)-3-(3-nitrophenyl)propionic acid benzyl ester (compound (A10)) from compound (A9)

[0568]

[0569] To a stirred solution of (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3-nitrophenyl)propanoic acid (5.00 g, 16.1 mmol) and BnBr (3.31 g, 19.3 mmol) in acetone (100 mL) was added KCO (4.45 g, 32.2 mmol). The resulting mixture was stirred at 50 °C overnight. The resulting mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent pentane / EtOAc 10:1) to give the title compound (4.0 g) pure enough for the next step.

[0570] Preparation of (S)-3-(3-aminophenyl)-2-((tert-butoxycarbonyl)amino)propionic acid benzyl ester (compound (A11)) from compound (A10)

[0571]

[0572] To a stirred solution of (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3-nitrophenyl)benzyl propionate (4.0 g, 9.9 mmol) and NH4Cl (2.14 g, 40 mmol) in EtOH (100 mL) and H2O (25 mL) was added Fe (1.67 g, 30 mmol). The resulting mixture was stirred at 80 °C for 3 hours. The resulting mixture was diluted with water (200 mL) and approximately 100 mL of solvent was removed under vacuum. The resulting mixture was extracted with EtOAc (2 x 100 mL) and the combined organic extracts were concentrated. The residue was purified by silica gel column chromatography (eluent: pentane / EtOAc 5:1) to obtain a sufficiently pure title compound (3.1 g) for the next step.

[0573] Preparation of (S)-3-(3-(((((4aR,10aR)-7-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]-quinolin-6-yl)oxy)carbonyl)amino)phenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid benzyl ester (compound (A12)) from compound (A11)

[0574]

[0575] To a stirred solution of (2S)-3-(3-aminophenyl)-2-[(tert-butoxycarbonyl)amino]benzyl propionate (928 mg, 2.5 mmol) and triphosgene (297 mg, 1.0 mmol) in DCM (30 mL) was added Et3N (845 mg, 8.4 mmol) at 0 °C. The resulting mixture was stirred at 0 °C for 1 hour, followed by addition of (4aR, 10aR)-7-(benzyloxy)-1-propyl-2H, 3H, 4H, 4aH, 5H, 10H, 10aH-benzo [g] quinoline-6-ol hydrogen iodide (1.00 g, 2.1 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water / ice (50 mL). The aqueous layer was extracted with DCM (3 x 50 mL). The combined organic extracts were concentrated. The residue was purified by reverse phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, MeCN in water (0.05% TFA), gradient 0% to 65% over 40 minutes; detector, UV 220 nm to afford the title compound (730 mg) pure enough for the next step.

[0576] Preparation of (S)-2-amino-3-(3-(((((4aR,10aR)-7-(benzyloxy)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)carbonyl)amino)phenyl)propanoic acid benzyl ester trifluoroacetate (compound (A13)) from compound (A12)

[0577]

[0578] To a stirred solution of benzyl 3-[3-[([[(4aR,10aR)-7-(benzyloxy)-1-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinolin-6-yl]oxy]carbonyl)amino]phenyl]-2-[(tert-butoxycarbonyl)amino]propanoate (730 mg, 1.0 mmol) in DCM (15 mL) was added TFA (3.0 mL). The resulting mixture was stirred at room temperature for 6 hours after which it was concentrated to give the title compound (810 mg) pure enough for the next step.

[0579] Preparation of (S)-2-amino-3-(3-(((((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)carbonyl)amino)phenyl)propanoic acid (Compound (6)) from Compound (A13)

[0580]

[0581] To a solution of benzyl 3-[3-[([[(4aR,10aR)-7-(benzyloxy)-1-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinolin-6-yl]oxy]carbonyl)amino]phenyl]-2-aminopropanoate trifluoroacetate (810 mg, 1.3 mmol) in MeOH (100 mL) was added Pd(OH)2 / C (0.2 g, 10%) in a 250 mL round bottom flask under nitrogen atmosphere. The mixture was hydrogenated using a hydrogen balloon at room temperature for 2 h, filtered through a pad of celite and concentrated. The residue was purified by preparative HPLC under the following conditions (column: XBridge Shield RP18 OBD column, 19*250 mm, 10 um; mobile phase A: water (0.05% TFA), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 10% B to 12% B in 10 minutes; 254 nm) to give the title compound (380 mg).

[0582] LC / MS: retention time: 1.71 min; UV-purity: 96.1; (ES, m / z): [M+H] + 468. Instrument: Shimadzu LCMS-2020 equipped with Shim-Pack XR-ODS C18, L=50 mm, D=3.0 mm column operated at 40°C. Mobile phase A: 0.05% TFA in water; Mobile phase B: 0.05% TFA in acetonitrile. Flow rate 1.2 mL / min. Gradient: 0-3.2 min A:B 95:5; 3.2 min-3.7 min: A:B 1:1; 3.7 min-4.75 min: A:B 0:1; 4.75 min-5.0 min: A:B 95:5.

[0583] 1 H NMR (400MHz, DMSO) δ7.73-7.41(d,2H),7.30-7.26(t,1H),6.95-6.93(d,1H),6.90-6.88(d,1H),6.80-6.78(d,1H),4.14-4.11(t,1H) ,3.54-3.51(d,1H),3.28-3.0(m,5H),2.87-2.78(m,3H),2.32-2.28(m,1H),1.91-1.66(m,6H),1.40-1.30(m,1H),0.98-0.95(t,3H).

[0584] In vitro and in vivo characterization of compounds of the invention

[0585] Example 1: Conversion of compounds of the invention in human plasma

[0586] Frozen human plasma is thawed, and then centrifuged at 3200x g for 5 minutes to remove debris.Then the pH value of the supernatant is measured and adjusted to 7.4 ± 0.1 by adding 1% phosphoric acid or 1N sodium hydroxide.2 μL dosing solutions (50 μM for test compound and 100 μM (propantheline bromide) for positive control) are mixed with 98 μL blank plasma, to obtain the ultimate concentration of 1 μM test compound and 2 μM positive control.At 37 ℃ in a water bath, the mixture is incubated, and samples are taken out at the predetermined time point of 0,0.5,1,2,4 and 6 hours (in duplicate) from the incubation.10 μL inhibitors and 20 μL ascorbic acid and 2 μL formic acid (20%) are added at each corresponding time point, and then 400 μL " stop solution " (200ng / mL tolbutamide plus 200ng / mL labetalol in 50%ACN / MeOH) are added to precipitate protein. The material was mixed thoroughly and thereafter centrifuged at 4,000 rpm for 20 minutes. An aliquot of the supernatant (50 μL) was then transferred from each well to a sample plate and mixed with 100 μL of ultrapure water. The plate was shaken at 800 rpm for approximately 10 minutes before being subjected to LC-MS / MS analysis.

[0587] Instrumentation for analysis of plasma incubation samples

[0588] Mass spectrometer (LC-MS / MS): Shimadzu LC 20-AD Shimadzu UHPLC API 4000. Analytical column: ACQUITY BEH Phenyl 1.7 μm 2.1×50 mm. Mobile phase A: 0.1% formic acid in water. Mobile phase B: 0.1% formic acid in acetonitrile. Gradient was run from 95% / 5% to 5% / 95% over 2.0 minutes. Flow rate 0.7 mL / min. MRM monitoring (multiple reaction monitoring) of test items and added analytical standards (labetalol or tolbutamide).

[0589] Example 2: 5-HT2B agonist activity and binding assays

[0590] 5-HT2B agonist activity assay

[0591] The evaluation of the agonist activity of compounds (I), (Ia) and (Ib) on the human 5-HT2B receptor was performed by Eurofins / Cerep (France) using the HTRF detection method to measure the effect of the compounds on the production of inositol-phosphate (IP1). Briefly, the human 5-HT2B receptor was expressed in transfected CHO cells. The cells were suspended in a buffer containing 10mM Hepes / NaOH (pH 7.4), 4.2mM KCl, 146mM NaCl, 1mM CaCl2, 0.5mM MgCl2, 5.5mM glucose and 50mM LiCl, then distributed in a microplate at a density of 4100 cells / well and incubated at 37°C for 30min in the presence of buffer (basal control), test compound or reference agonist. For control measurements of stimulation, separate assay wells contained 1μM 5-HT. After incubation, the cells were lysed and the fluorescent acceptor (fluorobenzene D2-labeled IP1) and the fluorescent donor (anti-IP1 antibody labeled with europium cryptate) were added. After 60 minutes at room temperature, the fluorescence transfer was measured at λ(Ex) 337nm and λ(Em) 620 and 665nm using a microplate reader (Rubystar, BMG). The IP1 concentration was determined by dividing the signal measured at 665nm by the signal measured at 620nm (ratio). The results were expressed as a percentage of the control in response to 1 μM 5-HT. The standard reference agonist was 5-HT, which was tested at several concentrations in each experiment to generate a concentration-response curve, from which its EC was calculated as described above for the dopamine function assay. 50 value.

[0592] 5-HT2B binding assay

[0593] Evaluation of compound affinity for the human 5-HT2B receptor was determined in a radioligand binding assay at Eurofins / Cerep (France). Membrane homogenates prepared from CHO cells expressing the human 5HT2B receptor were incubated with 0.2 nM [125I] (±) DOI (1-(4-iodo-2,5-dimethoxyphenyl) propan-2-amine) in a buffer containing 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 10 μM pargyline and 0.1% ascorbic acid at room temperature for 60 minutes in the absence or presence of test compounds. Nonspecific binding was determined in the presence of 1 μM (±) DOI. After incubation, the samples were quickly filtered under vacuum through glass fiber filters (GF / B, Packard) pre-soaked with 0.3% polyethyleneimine (PEI) using a 96-sample cell collector (Unifilter, Packard) and rinsed several times with ice-cold 50 mM Tris-HCl. The filters were dried and the radioactivity was counted in a scintillation counter (Topcount, Packard) using a scintillation cocktail (Microscint0, Packard). The results were expressed as a percentage inhibition of specific binding of the control radioligand. The standard reference compound was (±) DOI, which was tested at several concentrations in each experiment to obtain a competition curve from which its IC was calculated. 50 .

[0594] Table 3. In vitro activities of compounds (1)-(3) of the present invention obtained according to Example 2

[0595]

[0596]

[0597] *Indicated binding affinity (% inhibition of control, specific binding at indicated concentrations)

[0598] Example 3: PK study in rats

[0599] For all experiments, approximately 0.68 mL of blood samples were drawn from the tail vein or sublingual vein and placed in K3EDTA tubes that had been pre-cooled and prepared with a stabilizing solution consisting of 80 μL of ascorbic acid and 40 μL of 100 mM D-glucaric acid 1,4 lactone in water. These tubes were gently inverted 6-8 times to ensure thorough mixing and then placed in wet ice. The collection tubes were placed in wet ice for up to 30 minutes until centrifugation. Once removed from the wet ice, centrifugation was started immediately. The samples were immediately placed back on wet ice after the centrifugation was completed. Three subsamples of 130 μL of plasma were transferred to each of three appropriately labeled cryo tubes (these tubes were pre-mixed and stored frozen before use) containing 6.5 μL of pre-cooled formic acid (20%). The tube caps were replaced immediately and the plasma solution was thoroughly mixed by gently inverting 6-8 times. Within 60 minutes after sampling, the samples were stored frozen at a nominal -70°C. Centrifugation conditions were at 3000G, at 4°C, for 10 minutes. After collection, the plasma was placed on water-ice. The final storage was at approximately -70°C.

[0600] Plasma samples were analyzed by solid phase extraction or direct protein precipitation followed by UPLC-MS / MS. Electrospray MS detection was used in positive ion mode, where specific mass-to-nuclear transitions of compound (I) were monitored and the reaction was calibrated using an internal standard. Concentration-time data were analyzed using standard software using appropriate non-compartmental techniques to obtain estimates of derived PK parameters.

[0601] Instrumental equipment for analysis of compound (I) from administration of compound (Ia):

[0602] Mass spectrometer (LC-MS / MS) Waters Acquity-Sciex API 5000. Analytical column Waters BEH UPLC Phenyl 100x 2.1 mm column, 1.7 μm particle size. Mobile phase A: 20 mM ammonium formate (aqueous) + 0.5% formic acid. Mobile phase B: acetonitrile. Gradient from 95% / 5% to 2 / 98 over 6.1 minutes. Flow rate 0.5 mL / min. MRM monitoring (multiple reaction monitoring) of test items and added analytical standards.

[0603] Drug administration and blood sampling:Han Wistar rats were provided by Charles River Laboratories, Sulzfeld, Germany. An artificial, controlled, light-dark cycle of 12 h was maintained. The rats received a standard laboratory diet from Brogaarden (Altromin 1324 pellets). The rats had received this diet without restriction. During the study period (4-week toxicity study), the rats received oral administration of (Ia) once a day by gavage. Blood samples from 3 male satellite animals were collected from rats given 300 μg / kg of (Ia) at the following time points on day 29 after administration: 0.5, 1, 2, 4, 6, 8, 12 and 24 hours.

[0604] Instrumental equipment for analysis of compound (I) from administration of compound (Ib):

[0605] Mass spectrometer (LC-MS / MS) Waters Acquity-Sciex API 5000. Analytical column Waters BEH UPLC Phenyl 100x 2.1 mm column, 1.7 μm particle size. Mobile phase A: 20 mM ammonium formate (aqueous) + 0.5% formic acid. Mobile phase B: acetonitrile. Gradient from 95% / 5% to 2 / 98 over 6.1 minutes. Flow rate 0.5 mL / min. MRM monitoring of test items and added analytical standards.

[0606] Drug administration and blood sampling: Han Wistar rats were provided by Charles River Laboratories, UK. An artificial, controlled, light-dark cycle of 12 h was maintained. Rats received a standard laboratory diet (Teklad 2014C diet). Rats had received this diet ad libitum. During the study period (26-week toxicity study), rats received oral administration of (Ib) once daily by gavage. Blood samples from 3 male satellite animals were collected from rats given 300 μg / kg (Ib) at the following time points on day 182 after dosing: 0.5, 1, 2, 4, 8 and 24 hours.

[0607] Instrumentation for analysis of compound (I) from administration of compound (Ic), compound (1), compound (2), and compound (3)

[0608] Mass spectrometer (LC-MS / MS) Waters Acquity-Waters Xevo TQ-S. Analytical column Acquity BEH C18 100x 2.1mm, 1.7μm. Mobile phase A: 20mM NH4-formate + 0.2% formic acid. Mobile phase B: acetonitrile + 0.2% formic acid. Gradient was run from 95% / 5% to 5% / 95% over 11.0 minutes. Flow rate 0.3mL / min. MRM monitoring of test items and added analytical standards.

[0609] Drug administration and blood sampling: Han Wistar rats were provided by Envigo, UK. An artificial, controlled, light-dark cycle of 12 hours was maintained. Rats received a standard laboratory diet, Teklad 2014C. Rats had received this diet without restriction. Male Han Wistar rats were administered a single oral gavage administration of the test compound, orally by gavage. Rats were given 494 μg / kg (Ic), 0.505 mg / kg compound (1), 0.505 mg / kg compound (2) and 0.430 mg / kg compound (3). Blood samples from 3 male animals were collected at the following time points on day 1 after dosing: 1, 2, 4, 6, 8 and 24 hours.

[0610] Table 4. According to Example 3, 0.300 mg / kg (Ia), 0.300 mg / kg (Ib), 494 μg / kg (Ic), 0.505 0.505 mg / kg of compound (1), 0.505 mg / kg of compound (2) and 0.430 mg / kg of compound (3) were orally administered to Wistar rats. After that, (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (Compound (I)) PK parameters.

[0611]

[0612] Example 4: Competitive binding studies

[0613] The following assay as described in WO 06014429 was used to determine the binding affinity of the amino acid or peptide carbamate derivatives of the invention to hPEPT1:

[0614] The Ki values ​​of amino acid or peptide-carbamate derivative compounds (1)-(6) can be determined in a hPEPT1 overexpressing cell line (DC5) using 3H glycine-sarcosine (Gly-Sar). DC5 cells were seeded (12,000 cells / well) in 96-well tissue culture plates (Falcon) and allowed to grow for 4 days. The cells were washed once with 200 μL of aspiration buffer and aspirated. The plates were cooled to 4°C and 25 μL of aspiration buffer containing 50 μM Gly-Sar (0.5 μCi / ml) was added. The aspiration buffer also contained a range of test compounds. Aspiration was initiated by placing the plates in a shaking water bath (37°C) and terminated at 10 minutes by rapid washing with multiple changes of 4°C PBS (Sigma). Radioactive peptides were extracted from the cell layer using 200 μL of methanol:water (1:1) and counted in 4 mL of CytoScint ESTM scintillation cocktail (ICN). Nonlinear regression analysis of the data was used to determine the IC50 using the solve function in Microsoft Excel.

Claims

1. A compound selected from the group consisting of: (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(methylcarbamate); (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(ethylcarbamate); and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(dimethylcarbamate); or A pharmaceutically acceptable salt of any of these compounds.

2. The compound according to claim 1, which is selected from: (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(methylcarbamate); or or pharmaceutically acceptable salts thereof.

3. The compound according to claim 1, which is selected from: (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(ethylcarbamate); or or pharmaceutically acceptable salts thereof.

4. The compound according to claim 1, which is selected from: (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(dimethylcarbamate); or or pharmaceutically acceptable salts thereof.

5. A pharmaceutical composition comprising the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. The pharmaceutical composition according to claim 5 , wherein the pharmaceutical composition is for oral administration.

7. Use of the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating Parkinson's disease.

Citation Information

Patent Citations

  • (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers

    US4543256A

  • Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use

    WO2001078713A1

  • PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF

    WO2002100377A1

  • Cidofovir peptide conjugates as prodrugs

    WO2006014429A2

  • Catecholamine derivatives useful for the treatment of parkinson' s disease

    WO2009026934A1